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PRODUCTION OF STEVOL, GLYCOSDES 
IN RECOMBIANT HOSTS 
BACKGROUND OF THE INVENTION 
0001 Field of the Invention 
0002 This disclosure relates generally to the recombi 
nant production of Steviol glycosides such as rebaudioside A 
(RebA), rebaudioside B (RebB), rebaudioside D (RebD), 
and rebaudioside M (RebM) by recombinant hosts such as 
recombinant microorganisms and isolation methods thereof. 
In particular, this disclosure relates to modifications to 
transport systems in a recombinant host to increase produc 
tion of Such Steviol glycosides and/or transport of Such 
Steviol glycosides into the culture medium. 
0003. Description of Related Art 
0004 Sweeteners are well known as ingredients used 
most commonly in the food, beverage, or confectionary 
industries. The sweetener can either be incorporated into a 
final food product during production or for stand-alone use, 
when appropriately diluted, as a tabletop Sweetener or an 
at-home replacement for Sugars in baking. Sweeteners 
include natural Sweeteners such as Sucrose, high fructose 
corn Syrup, molasses, maple syrup, and honey and artificial 
Sweeteners such as aspartame, Saccharine, and Sucralose. 
Stevia extract is a natural Sweetener that can be isolated and 
extracted from a perennial shrub, Stevia rebaudiana. Stevia 
is commonly grown in South America and Asia for com 
mercial production of Stevia extract. Stevia extract, purified 
to various degrees, is used commercially as a high intensity 
sweetener in foods and in blends or alone as a tabletop 
SWeetener. 
0005 Chemical structures for several steviol glycosides 
are shown in FIG. 1, including the diterpene steviol and 
various Steviol glycosides. Extracts of the Stevia plant 
generally comprise rebaudiosides and other Steviol glyco 
sides that contribute to the sweet flavor, although the amount 
of each Steviol glycoside often varies, inter alia, among 
different production batches. 
0006. As recovery and purification of steviol glycosides 
from the Stevia plant have proven to be labor intensive and 
inefficient, there remains a need for a recombinant produc 
tion system that can produce high yields of desired Steviol 
glycosides, such as RebD and RebM. 
SUMMARY OF THE INVENTION 
0007. It is against the above background that the present 
invention provides certain advantages and advancements 
over the prior art. 
0008. In particular, the invention provides a recombinant 
host capable of synthesizing a Steviol glycoside, comprising 
a gene encoding a transporter polypeptide and/or a gene 
encoding a transcription factor polypeptide that regulates 
expression of at least one transporter gene; wherein expres 
sion of the gene encoding the transporter polypeptide and/or 
the gene encoding the transcription factor polypeptide that 
regulates expression of at least one transporter gene is 
modified and the recombinant host transports at least a 
portion of the synthesized steviol glycoside from the host 
into a culture medium. 
0009. In some aspects of the recombinant host disclosed 
herein, the gene encoding the transporter polypeptide is an 
endogenous gene. 
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0010. In some aspects of the recombinant host disclosed 
herein, the transporter polypeptide comprises an ATP-bind 
ing cassette (ABC) transporter, a major facilitator Superfam 
ily (MFS) transporter, an amino acid/auxin permease 
(AAAP) family transporter, ATPase transporter, a sulfate 
permease (SulP) family transporter, a lysosomal cystine 
transporter (LCT) family transporter, a Ca2+:cation anti 
porter (CaCA) family transporter, an amino acid-polyamine 
organocation (APC) Superfamily transporter, a multidrug/ 
oligosaccharidyl-lipid/polysaccharide (MOP) transporter, a 
ZRT/IRT-like protein (ZIP) metal transporter family trans 
porter, a mitochondrial protein translocase (MPT) family 
transporter, a Voltage-gated ion channel (VIC) family trans 
porter, a monovalent cation: proton antiporter-2 (CPA2) fam 
ily transporter, a ThrE family of putative transmembrane 
amino acid efflux transporter, an oligopeptide transporter 
(OPT) family transporter, a K transporter (Trk) family 
transporter, a bile acid:Na symporter (BASS) family trans 
porter, a drug/metabolite transporter (DMT) superfamily 
transporter, a mitochondrial carrier (MC) family transporter, 
an auxin efflux carrier (AEC) family transporter, an ammo 
nia channel transporter (Amt) family transporter, a metalion (Mn"-iron) transporter (Nramp) family transporter, a tran 
sient receptor potential Ca" channel (TRP-CC) family 
transporter, an arsenical resistance-3 (ACR3) family trans 
porter, a nucleobase:cation symporter-1 (NCS1) family 
transporter, an inorganic phosphate transporter (PiT) family 
transporter, an arsenite-antimonite (Ars AB) efflux family 
transporter, an IISP family of transporter, a glycerol uptake 
(GUP) family transporter, a metal ion transport (MIT) 
family transporter, a copper transport (Ctr) family or a cation 
diffusion facilitator (CDF) family transporter. 
0011. In some aspects of the recombinant host disclosed 
herein, the modified expression comprises modified expres 
sion comprises: 
0012 (a) overexpressing the gene encoding the trans 
porter polypeptide and/or the gene encoding the tran 
Scription factor polypeptide; or 
0013 (b) deleting the gene encoding the transporter 
polypeptide and/or the gene encoding the transcription 
factor polypeptide. 
0014. In some aspects of the recombinant host disclosed 
herein, the gene encoding the transporter polypeptide and/or 
the gene encoding the transcription factor polypeptide has an 
activity that is increased. 
0015. In some aspects of the recombinant host disclosed 
herein, one or more of the genes encoding the transporter 
polypeptide and/or one or more of the genes encoding the 
transcription factor polypeptide are overexpressed. 
0016. In some aspects of the recombinant host disclosed 
herein, the transporter polypeptide and/or transcription poly 
peptide comprise YAL067C set forth in SEQ ID NO:14, 
YBL089W set forth in SEQID NO:15, YBL099W set forth 
in SEQ ID NO:16, YBR008C set forth in SEQ ID NO:86, 
in SEQ ID NO:91, YCL038C set forth in SEQ ID NO:92, 
YCL069W set forth in SEQID NO:19, YCR011C set forth 
in SEQ ID NO:93, YCR028C set forth in SEQ ID NO:20, 
YCR075C set forth in SEQID NO:21, YDL054C set forth 
in SEQ ID NO:94, YDL100C set forth in SEQ ID NO:95, 
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YDL128W set forth in SEQID NO:22, YDL185W set forth 
in SEQ ID NO:23, YDL194W set forth in SEQID NO:24, 
YDL210W set forth in SEQ ID NO:25, YDL245C set forth 
in SEQ ID NO:96, YDL247W set forth in SEQID NO:97, 
YDR011W set forth in SEQID NO:98, YDR061W set forth 
in SEQ ID NO:26, YDR093W set forth in SEQ ID NO:27, 
YDR292C set forth in SEQ ID NO:99, YDR338C set forth 
in SEQ ID NO:28, YDR406W set forth in SEQ ID NO:29, 
YDR497C set forth in SEQID NO:100, YDR536W set forth 
in SEQID NO:30, YEL006W set forth in SEQ ID NO:101, 
YEL027W set forth in SEQID NO:102, YEL031W set forth 
in SEQID NO:31, YEL065W set forth in SEQ ID NO:103, 
YER019C-A set forth in SEQ ID NO:104, YER053C set 
forth in SEQ ID NO:105, YER119C set forth in SEQ ID 
NO:106, YER166W set forth in SEQID NO:32, YFLO11W 
set forth in SEQ ID NO:33, YFLO28C set forth in SEQ ID 
NO:107, YFR045W set forth in SEQ ID NO:108, 
YGL006W set forth in SEQ ID NO:34, YGL013C set forth 
in SEQID NO:35, YGL084C set forth in SEQ ID NO:109, 
YGL104C set forth in SEQID NO: 110, YGL114W set forth 
in SEQID NO:111, YGL167C set forth in SEQID NO:112, 
YGL255W set forth in SEQID NO:36, YGR125W set forth 
in SEQ ID NO:37, YGR181W set forth in SEQ ID NO:38, 
YGR217W set forth in SEQID NO:39, YGR224W set forth 
in SEQID NO:40, YGR257C set forth in SEQID NO:113, 
YGR281 W set forth in SEQID NO:41, YHL016C set forth 
in SEQ ID NO:42, YHL035C set forth in SEQ ID NO:114, 
YHL036W set forth in SEQ ID NO:115, YHR002W set 
forth in SEQ ID NO:116, YHR096C set forth in SEQ ID 
NO:117, YIL006W set forth in SEQ ID NO:118, YIL088C 
set forth in SEQ ID NO:43, YIL120W set forth in SEQ ID 
NO: 119, YIL121W set forth in SEQ ID NO:120, YIL166C 
set forth in SEQID NO:121, YJL093C set forth in SEQ ID 
NO:44, YJL094C set forth in SEQID NO:45, YJL108C set 
forth in SEQ ID NO:46, YJL133W set forth in SEQ ID 
NO: 122, YJL212C set forth in SEQ ID NO:47, YJL219W 
set forth in SEQID NO:123, YJR106W set forth in SEQ ID 
NO:48, YJR160C set forth in SEQID NO:49, YKL016C set 
forth in SEQ ID NO.124, YKL050C set forth in SEQ ID 
NO:125, YKL064W set forth in SEQID NO:50, YKL120W 
set forth in SEQID NO.126, YKL146W set forth in SEQID 
NO: 127, YKL209C set forth in SEQ ID NO: 128, 
YKR039W set forth in SEQ ID NO:129, YKR050W set 
forth in SEQ ID NO:51, YKR105C set forth in SEQ ID 
NO:52, YKR106W set forth in SEQ ID NO:53, YLR411W 
set forth in SEQID NO: 130, YLR447C set forth in SEQ ID 
NO:54, YML038C set forth in SEQID NO:131, YML116W 
set forth in SEQID NO:55, YMR034C set forth in SEQ ID 
NO:56, YMR056C set forth in SEQ ID NO:57, YMR166C 
set forth in SEQID NO: 132, YMR253C set forth in SEQID 
NO:58, YMR279C set forth in SEQID NO:133, YNL003C 
set forth in SEQID NO:134, YNL065W set forth in SEQID 
NO:59, YNL07OW set forth in SEQ ID NO:60, YNL083W 
set forth in SEQ ID NO:61, YNL095C set forth in SEQ ID 
NO:62, YNL121C set forth in SEQID NO:63, YNL142W 
set forth in SEQID NO:64, YNL268W set forth in SEQ ID 
NO:135, YNR055C set forth in SEQ ID NO:136, 
YOLO2OW set forth in SEQ ID NO:65, YOLO75C set forth 
in SEQID NO:66, YOLO77W-A set forth in SEQID NO:67, 
YOL122C set forth in SEQ ID NO:68, YOL158C set forth 
in SEQ ID NO:137, YOR079C set forth in SEQ ID NO:69, 
YOR087W set forth in SEQID NO:70, YOR092W set forth 
in SEQ ID NO:71, YOR100C set forth in SEQ ID NO: 138, 
YOR130C set forth in SEQID NO:72, YOR153W set forth 
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in SEQID NO:139, YOR222W set forth in SEQID NO:73, 
YOR271C set forth in SEQID NO:140, YOR273C set forth 
in SEQID NO:141, YOR291W set forth in SEQID NO:74, 
YOR306C set forth in SEQ ID NO:75, YOR307C set forth 
in SEQ ID NO:142, YOR316C set forth in SEQ ID NO:76, 
YOR332W set forth in SEQ ID NO:143, YOR334W set 
forth in SEQ ID NO:77, YOR348C set forth in SEQ ID 
NO:144, YPL036W set forth in SEQID NO:145, YPL078C 
set forth in SEQ ID NO:78, YPL27OW set forth in SEQ ID 
NO:79,YPL274W set forth in SEQID NO:80, YPR003C set 
forth in SEQ ID NO:81, YPR011C set forth in SEQ ID 
NO:82, YPR058W set forth in SEQ ID NO:83, YPR128C 
set forth in SEQ ID NO:84, or YPR201W set forth in SEQ 
ID NO:85. 
0017. In some aspects of the recombinant host disclosed 
herein, YBR043C set forth in SEQID NO:88, YDL100C set 
forth in SEQ ID NO:95, YDL054C set forth in SEQ ID 
NO:94, YDL128W set forth in SEQID NO:22, YDL198C 
set forth in SEQID NO:146, YDR061W set forth in SEQID 
NO:26, YDR536W set forth in SEQ ID NO:30, YEL027W 
set forth in SEQ ID NO:102, YFLO54C set forth in SEQ ID 
NO:147, YGL167C set forth in SEQID NO:112, YGR181W 
set forth in SEQ ID NO:38, YHL016C set forth in SEQ ID 
NO:42, YIL166C set forth in SEQID NO:121, YJL093C set 
forth in SEQ ID NO:44, YJR106W set forth in SEQ ID 
NO:48, YKL120W set forth in SEQID NO: 126, YKL146W 
set forth in SEQID NO.127, YKR039W set forth in SEQID 
NO:129, YMR034C set forth in SEQID NO:56, YMR166C 
set forth in SEQID NO:132, YOL122C set forth in SEQID 
NO:68, YOR079C set forth in SEQ ID NO:69, YPL27OW 
set forth in SEQ ID NO:79, and/or YPR011C set forth in 
SEQ ID NO:82 are overexpressed. 
0018. In some aspects, the recombinant host further com 
prises: 
0019 (a) one or more genes encoding a Sucrose trans 
porter and a Sucrose synthase; 
0020 (b) a gene encoding a geranylgeranyl diphos 
phate synthase (GGPPS) polypeptide: 
0021 (c) a gene encoding an ent-copalyl diphosphate 
synthase (CDPS) polypeptide; 
0022 (d) a gene encoding a kaurene synthase (KS) 
polypeptide; 
0023 (e) a gene encoding a kaurene oxidase (KO) 
polypeptide; 
0024 (f) a gene encoding a steviol synthase (KAH) 
polypeptide; 
0.025 (g) a gene encoding a cytochrome P450 reduc 
tase (CPR) polypeptide; 
0026 (h) a gene encoding a UGT85C2 polypeptide; 
0027 (i) a gene encoding a UGT76G1 polypeptide; 
0028 (k) a gene encoding a UGT91D2 functional 
homolog; and/or 
0029 (1) a gene encoding a EUGT11 polypeptide; 
0030 wherein at least one of the genes is a recombi 
nant gene; and 
0.031 wherein the host is capable of producing one or 
more of RebA, RebB, RebD and/or RebM. 
0032. In some aspects of the recombinant host disclosed 
herein, at least one of the genes is codon optimized for 
expression in the host. 
0033. In some aspects of the recombinant host disclosed 
herein, at least one of the genes is codon optimized for 
expression in Saccharomyces cerevisiae. 
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0034. In some aspects of the recombinant host disclosed 
herein, 
0035 (a) the GGPPS polypeptide comprises a poly 
peptide having at least 70% identity to an amino acid 
sequence set forth in SEQ ID NO:149: 
0036 (b) the CDPS polypeptide comprises a polypep 
tide having at least 70% identity to an amino acid 
sequence set forth in SEQ ID NO:150; 
0037 (c) the KO polypeptide comprises a polypeptide 
having at least 70% identity to an amino acid sequence 
set forth in SEQ ID NO:152: 
0038 (d) the KS polypeptide comprises a polypeptide 
having at least 40% identity to an amino acid sequence 
set forth in SEQ ID NO:151: 
0039 (e) the KAH polypeptide comprises a polypep 
tide having at least 60% identity to an amino acid 
sequence set forth in SEQ ID NO:154; 
0040 (f) the CPR polypeptide comprises a polypeptide 
having at least 70% identity to an amino acid sequence 
set forth in SEQ ID NO:153 and/or a polypeptide 
having at least 65% identity to an amino acid sequence 
set forth in SEQ ID NO:155; 
0041 (g) the UGT85C2 polypeptide comprises a poly 
peptide having at least 55% identity to an amino acid 
sequence set forth in SEQ ID NO:156: 
0042 (h) the UGT76G1 polypeptide comprises a poly 
peptide having at least 50% identity to an amino acid 
sequence set forth in SEQ ID NO:158: 
0043 (i) the UGT74G1 polypeptide comprises a poly 
peptide having at least 55% identity to an amino acid 
sequence set forth in SEQ ID NO:157: 
0044) () the a UGT91D2 functional homolog com 
prises a UGT91D2e-b polypeptide having at least 90% 
identity to the amino acid sequence set forth in SEQID 
NO:159; and 
0045 (k) the EUGT11 polypeptide comprises a poly 
peptide having at least 65% identity to an amino acid 
sequence set forth in SEQ ID NO:148. 
0046. In some aspects, the recombinant host disclosed 
herein comprises a microorganism that is a plant cell, a 
mammalian cell, an insect cell, a fungal cell, or a bacterial 
cell. 
0047. In some aspects, the bacterial cell comprises 
Escherichia bacteria cells, Lactobacillus bacteria cells, Lac 
tococcus bacteria cells, Cornebacterium bacteria cells, 
Acetobacter bacteria cells, Acinetobacter bacteria cells, or 
Pseudomonas bacterial cells. 
0048. In some aspects, the fungal cell is a yeast cell. 
0049. In some aspects, the yeast cell is a cell from 
Saccharomyces cerevisiae, Schizosaccharomyces pombe, 
Yarrowia lipolytica, Candida glabrata, Ashbya gossypii, 
Cyberlindnerajadinii, Pichia pastoris, Kluyveromyces lac 
tis, Hansenula polymorpha, Candida boidinii, Arxula 
adeninivorans, Xanthophyllomyces dendrorhous, or Can 
dida albicans species. 
0050. In some aspects, the yeast cell is a Saccharomycete. 
0051. In some aspects, the yeast cell is a cell from the 
Saccharomyces cerevisiae species. 
0052. The invention further provides a method of pro 
ducing a Steviol glycoside, comprising: 
0053 (a) growing the recombinant host disclosed 
herein in a culture medium, under conditions in which 
the genes comprising recombinant host disclosed 
herein are expressed, 
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0.054 wherein the steviol glycoside is synthesized by 
the host; and 
0.055 (b) optionally isolating the steviol glycoside. 
0056. In some aspects of the methods disclosed herein, 
the steviol glycoside is RebA, RebB, RebD, and/or RebM. 
and wherein: 
0057 (a) RebA is capable of being synthesized in the 
recombinant host disclosed herein expressing 
UGT85C2, UGT76G1, UGT74G1, and UGT91D2: 
0.058 (b) RebB is capable of being synthesized in the 
recombinant host disclosed herein expressing 
UGT85C2, UGT76G1, and UGT91D2: 
0059 (c) RebD is capable of being synthesized in the 
recombinant host disclosed herein expressing 
UGT85C2, UGT76G1, UGT74G1, and UGT91D2 and/ 
or EUGT11; and 
0060 (d) RebM is capable of being synthesized in the 
recombinant host disclosed herein expressing 
UGT85C2, UGT76G1, UGT74G1, and UGT91D2 and/ 
Or EUGT11 
0061. In some aspects of the methods disclosed herein a 
gene encoding YBR043C set forth in SEQ ID NO:88, 
YDL100C set forth in SEQID NO:95, YDL054C set forth 
in SEQ ID NO:94, YDL128W set forth in SEQID NO:22, 
YDL198C set forth in SEQID NO:146, YDR061W set forth 
in SEQ ID NO:26, YDR536W set forth in SEQID NO:30, 
YEL027W set forth in SEQ ID NO:102, YFLO54C set forth 
in SEQID NO: 147, YGL167C set forth in SEQID NO:112, 
YGR181W set forth in SEQID NO:38, YHL016C set forth 
in SEQ ID NO:42, YIL166C set forth in SEQ ID NO:121, 
YJL093C set forth in SEQID NO:44, YJR106W set forth in 
SEQ ID NO:48, YKL120W set forth in SEQ ID NO: 126, 
YKL146W set forth in SEQ ID NO:127, YKR039W set 
forth in SEQ ID NO.129, YMR034C set forth in SEQ ID 
NO:56, YMR166C set forth in SEQ ID NO: 132, YOL122C 
set forth in SEQ ID NO:68, YOR079C set forth in SEQ ID 
NO:69, YPL27OW set forth in SEQ ID NO:79, and/or 
YPR011C set forth in SEQ ID NO:82 is overexpressed. 
0062. In some aspects of the methods disclosed herein the 
Steviol glycoside is produced at a concentration of between 
about 500 mg/L to about 10,000 mg/L. 
0063. The invention further provides a method of increas 
ing production or transport of a Steviol glycoside into a 
culture medium, comprising: 
0.064 (a) growing the recombinant host disclosed 
herein in a culture medium, under conditions in which 
the genes comprising the host disclosed herein are 
expressed, 
0065 wherein the steviol glycoside is synthesized by 
the host; and 
0.066 (b) optionally isolating the steviol glycoside. 
0067. In some aspects of the methods disclosed herein, 
the steviol glycoside is RebA, RebB, RebD, and/or RebM. 
0068. The invention further provides a method increasing 
production of Steviol or a Steviol glycoside in a recombinant 
host, comprising modifying expression of a gene encoding 
a transporter polypeptide and/or a gene encoding a tran 
Scription that regulates expression of at least one transporter 
gene, wherein the host is capable of transporting at least a 
portion of the produced Steviol or a steviol glycoside from 
the host into a culture medium. 
0069. These and other features and advantages of the 
present invention will be more fully understood from the 
following detailed description of the invention taken 
US 2017/021841 8 A1 
together with the accompanying claims. It is noted that the 
scope of the claims is defined by the recitations therein and 
not by the specific discussion of features and advantages set 
forth in the present description. 
DESCRIPTION OF DRAWINGS 
0070 FIG. 1 shows the chemical structures and synthesis 
pathways for various Steviol glycosides. 
0071 FIG. 2 is a bar graph of the amount (uM) of RebA, 
RebB, RebD, or RebM in the Supernatant of a steviol 
glycoside-producing strain overexpressing transporter genes 
YGR181W (SEQ ID NO:38) or YDR061W (SEQ ID 
NO:26), compared to a control Steviol glycoside-producing 
strain. See Example 4. 
0072 FIG. 3A and FIG. 3B are bar graphs of the amount 
(mg/L) of RebA, RebD, or RebM in the supernatant (FIG. 
3A) or total culture (FIG. 3B) of a YGR181W (SEQ ID 
NO:38) or YDR061W (SEQ ID NO:26) overexpressing 
strain, compared to a control Steviol glycoside-producing 
strain. See Example 4. 
0073 FIG. 4A shows levels of 13-SMG (total levels and 
supernatant levels; uM/ODoo), FIG. 4B shows levels of 
RebA (total levels and supernatant levels; uM/OD), FIG. 
4C shows levels of RebB (total levels and supernatant 
levels; uM/ODoo), FIG. 4D shows levels of RebD (total 
levels and supernatant levels; uM/OD), and FIG. 4E 
shows levels of RebM (total levels and supernatant levels; 
uM/ODoo) in a steviol glycoside-producing S. cerevisiae 
strain with a genomically integrated transporter gene. The 
genomically integrated transporter genes of FIGS. 4A-E are 
YBR043C (SEQID NO:88), YEL027W (SEQID NO:102), 
YJL093C (SEQ ID NO:44), YJR106W (SEQ ID NO:48), 
YMR166C (SEQ ID NO:132), YIL166C (SEQ ID NO:121), 
YKL120W (SEQID NO.126), YDL054C (SEQID NO:94), 
YDL128W (SEQ ID NO:22), YDR536W (SEQ ID NO:30), 
YGL167C (SEQ ID NO:112), YKL146W (SEQ ID 
NO:127), YKRO39W (SEQ ID NO:129), YOL122C (SEQ 
ID NO:68), and YPR011C (SEQ ID NO:82). See Example 
6 
0074 FIG. 5A shows supernatant levels of RebA, RebB, 
RebD, and RebM (in uM/ODoo) of a steviol glycoside 
producing strain overexpressing YMR166C (SEQ ID 
NO:132), YEL027W (SEQ ID NO:102), YKL120W (SEQ 
ID NO:126), YIL166C (SEQ ID NO:121), YJR106W (SEQ 
ID NO:48), YJL093C (SEQ ID NO:44), and YBR043C 
(SEQ ID NO:88) by the USER cloning system. FIG. 5B 
shows total levels of RebA, RebB, RebD, and RebM (in 
uM/ODoo) of a Steviol glycoside-producing strain overex 
pressing YMR166C (SEQID NO:132), YEL027W (SEQ ID 
NO:102), YKL120W (SEQID NO:126), YIL166C (SEQID 
NO:121), YJR106W (SEQ ID NO:48), YJL093C (SEQ ID 
NO:44), and YBR043C (SEQ ID NO:88) by the USER 
cloning System. 
DETAILED DESCRIPTION 
0075 All publications, patents and patent applications 
cited herein are hereby expressly incorporated by reference 
in their entirety for all purposes. 
0076. Before describing the present invention in detail, a 
number of terms will be defined. As used herein, the singular 
forms “a,” “an, and “the include plural referents unless the 
context clearly dictates otherwise. For example, reference to 
“a nucleic acid means one or more nucleic acids. 
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(0077. It is noted that terms like “preferably,” “com 
monly, and “typically' are not utilized herein to limit the 
Scope of the claimed invention or to imply that certain 
features are critical, essential, or even important to the 
structure or function of the claimed invention. Rather, these 
terms are merely intended to highlight alternative or addi 
tional features that can or cannot be utilized in a particular 
embodiment of the present invention. 
0078 For the purposes of describing and defining the 
present invention it is noted that the term “substantially' is 
utilized herein to represent the inherent degree of uncer 
tainty that can be attributed to any quantitative comparison, 
value, measurement, or other representation. The term "sub 
stantially' is also utilized herein to represent the degree by 
which a quantitative representation can vary from a stated 
reference without resulting in a change in the basic function 
of the Subject matter at issue. 
0079 Methods well known to those skilled in the art can 
be used to construct genetic expression constructs and 
recombinant cells according to this invention. These meth 
ods include in vitro recombinant DNA techniques, synthetic 
techniques, in vivo recombination techniques, and poly 
merase chain reaction (PCR) techniques. See, for example, 
techniques as described in Green & Sambrook, 2012, 
MOLECULAR CLONING: A LABORATORY MANUAL, 
Fourth Edition, Cold Spring Harbor Laboratory, New York; 
Ausubel et al., 1989, CURRENT PROTOCOLS IN 
MOLECULAR BIOLOGY, Greene Publishing Associates 
and Wiley Interscience, New York, and PCR Protocols: A 
Guide to Methods and Applications (Innis et al., 1990, 
Academic Press, San Diego, Calif.). 
0080. As used herein, the terms “polynucleotide.” 
“nucleotide,” “oligonucleotide,” and “nucleic acid can be 
used interchangeably to refer to nucleic acid comprising 
DNA, RNA, derivatives thereof, or combinations thereof. 
I0081. As used herein, the terms “microorganism.” 
“microorganism host,” “microorganism host cell,” “host 
cell,” “recombinant host,” “recombinant microorganism 
host, and “recombinant host cell can be used interchange 
ably. As used herein, the term “recombinant host' is 
intended to refer to a host, the genome of which has been 
augmented by at least one DNA sequence. Such DNA 
sequences include but are not limited to genes that are not 
naturally present, DNA sequences that are not normally 
transcribed into RNA or translated into a protein (“ex 
pressed’), and other genes or DNA sequences which one 
desires to introduce into the non-recombinant host. It will be 
appreciated that typically the genome of a recombinant host 
described herein is augmented through stable introduction of 
one or more recombinant genes. Generally, introduced DNA 
is not originally resident in the host that is the recipient of 
the DNA, but it is within the scope of this disclosure to 
isolate a DNA segment from a given host, and to Subse 
quently introduce one or more additional copies of that DNA 
into the same host, e.g., to enhance production of the product 
of a gene or alter the expression pattern of a gene. In some 
instances, the introduced DNA will modify or even replace 
an endogenous gene or DNA sequence by, e.g., homologous 
recombination or site-directed mutagenesis. Suitable recom 
binant hosts include microorganisms. 
I0082. As used herein, the term “recombinant gene’ refers 
to a gene or DNA sequence that is introduced into a recipient 
host, regardless of whether the same or a similar gene or 
DNA sequence may already be present in Such a host. 
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“Introduced,” or “augmented in this context, is known in 
the art to mean introduced or augmented by the hand of man. 
Thus, a recombinant gene can be a DNA sequence from 
another species or can be a DNA sequence that originated 
from or is present in the same species but has been incor 
porated into a host by recombinant methods to form a 
recombinant host. It will be appreciated that a recombinant 
gene that is introduced into a host can be identical to a DNA 
sequence that is normally present in the host being trans 
formed and is introduced to provide one or more additional 
copies of the DNA to thereby permit overexpression or 
modified expression of the gene product of that DNA. Said 
recombinant genes are particularly encoded by cDNA. 
0083. As used herein, the term “engineered biosynthetic 
pathway refers to a biosynthetic pathway that occurs in a 
recombinant host, as described herein, and does not natu 
rally occur in the host. 
0084 As used herein, the term “endogenous gene refers 
to a gene that originates from and is produced or synthesized 
within a particular organism, tissue, or cell. In some embodi 
ments, the endogenous gene is a yeast transporter. In some 
embodiments, the transporter is endogenous to S. cerevisiae, 
including, but not limited to S. cerevisiae strain S288C. In 
Some embodiments, an endogenous yeast transporter gene is 
overexpressed. As used herein, the term “overexpress” is 
used to refer to the expression of a gene in an organism at 
levels higher than the level of gene expression in a wild type 
organism. See, e.g., Prelich, 2012, Genetics 190:841-54. In 
Some embodiments, an endogenous yeast transporter gene is 
deleted. See, e.g., Giaever & Nislow, 2014, Genetics 197 
(2):451-65. As used herein, the terms “deletion,” “deleted.” 
“knockout,’ and “knocked out can be used interchangeably 
to refer to an endogenous gene that has been manipulated to 
no longer be expressed in an organism, including, but not 
limited to, S. cerevisiae. In some embodiments, a deleted/ 
knocked out gene is a transporter gene or a transcription 
factor gene that regulates expression of a transporter gene. 
0085. As used herein, the terms "heterologous sequence' 
and "heterologous coding sequence' are used to describe a 
sequence derived from a species other than the recombinant 
host. In some embodiments, the recombinant host is an S. 
cerevisiae cell, and a heterologous sequence is derived from 
an organism other than S. cerevisiae. A heterologous coding 
sequence, for example, can be from a prokaryotic microor 
ganism, a eukaryotic microorganism, a plant, an animal, an 
insect, or a fungus different than the recombinant host 
expressing the heterologous sequence. In some embodi 
ments, a coding sequence is a sequence that is native to the 
host. 
I0086 A “selectable marker' can be one of any number of 
genes that complement host cell auxotrophy, provide anti 
biotic resistance, or result in a color change. Linearized 
DNA fragments of the gene replacement vector then are 
introduced into the cells using methods well known in the art 
(see below). Integration of the linear fragments into the 
genome and the disruption of the gene can be determined 
based on the selection marker and can be verified by, for 
example, PCR or Southern blot analysis. Subsequent to its 
use in selection, a selectable marker can be removed from 
the genome of the host cell by, e.g., Cre-LOXP systems (see, 
e.g., Gossen et al., 2002, Ann. Rev. Genetics 36:153-173 and 
U.S. 2006/0014264). Alternatively, a gene replacement vec 
tor can be constructed in Such a way as to include a portion 
of the gene to be disrupted, where the portion is devoid of 
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any endogenous gene promoter sequence and encodes none, 
or an inactive fragment of the coding sequence of the gene. 
0087. As used herein, the terms “variant” and “mutant” 
are used to describe a protein sequence that has been 
modified at one or more amino acids, compared to the wild 
type sequence of a particular protein. 
I0088 As used herein, the term “inactive fragment” is a 
fragment of the gene that encodes a protein having, e.g., less 
than about 10% (e.g., less than about 9%, less than about 
8%, less than about 7%, less than about 6%, less than about 
5%, less than about 4%, less than about 3%, less than about 
2%, less than about 1%, or 0%) of the activity of the protein 
produced from the full-length coding sequence of the gene. 
Such a portion of a gene is inserted in a vector in Such a way 
that no known promoter sequence is operably linked to the 
gene sequence, but that a stop codon and a transcription 
termination sequence are operably linked to the portion of 
the gene sequence. This vector can be Subsequently linear 
ized in the portion of the gene sequence and transformed into 
a cell. By way of single homologous recombination, this 
linearized vector is then integrated in the endogenous coun 
terpart of the gene with inactivation thereof. 
I0089. As used herein, the term “steviol glycoside' refers 
to Rebaudioside A (RebA) (CAS #58543-16-1), Rebaudio 
side B (RebB) (CAS #58543-17-2), Rebaudioside C (RebC) 
(CAS #63550-99-2), Rebaudioside D (RebD) (CAS #63279 
13-0), Rebaudioside E (RebE) (CAS #63279-14-1), Rebau 
dioside F (RebF) (CAS #438.045-89-7), Rebaudioside M 
(RebM) (CAS #1220616-44-3), Rubusoside (CAS #63849 
39-4), Dulcoside A (CAS #64432-06-0), Rebaudioside I 
(RebI) (MassBank Record: FU000332), Rebaudioside Q 
(RebO), 1.2-Stevioside (CAS #57817-89-7), 1,3-Stevioside 
(RebG), 1.2-Bioside (MassBank Record: FU000299), 1,3- 
Bioside, Steviol-13-O-glucoside (13-SMG), Steviol-19-O- 
glucoside (19-SMG), a tri-glucosylated Steviol glycoside, a 
tetra-glycosylated Steviol glycoside, a penta-glucosylated 
Steviol glycoside, a hexa-glucosylated Steviol glycoside, a 
hepta-glucosylated Steviol glycoside, di-glucosylated 
kaurenoic acid, tri-glucosylated kaurenoic acid, di-glucosy 
lated kaurenol, tri-glucosylated kaurenol, and isomers 
thereof. 
0090 Recombinant steviol glycoside-producing Saccha 
romyces cerevisiae (S. cerevisiae) strains are described in 
WO 2011/153378, WO 2013/022989, WO 2014/122227, 
and WO 2014/122328, each of which has been incorporated 
by reference herein in its entirety. See, also, Example 2. 
Methods of producing Steviol glycosides in recombinant 
hosts, by whole cell bio-conversion, and in vitro are also 
described in WO 2011/153378, WO 2013/022989, WO 
2014/122227, and WO 2014/122328. 
0091. In some embodiments, steviol glycosides and/or 
Steviol glycoside precursors are produced in vivo through 
expression of one or more enzymes involved in the Steviol 
glycoside biosynthetic pathway in a recombinant host. For 
example, a Steviol-producing recombinant host expressing 
one or more of a gene encoding a geranylgeranyl diphos 
phate synthase (GGPPS) polypeptide, a gene encoding an 
ent-copalyl diphosphate synthase (CDPS) polypeptide, a 
gene encoding a kaurene synthase (KS) polypeptide, a gene 
encoding a kaurene oxidase polypeptide (KO), a gene 
encoding a Steviol synthase (KAH) polypeptide, a gene 
encoding a cytochrome P450 reductase (CPR) polypeptide, 
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and a gene encoding a UGT polypeptide can produce a 
Steviol glycoside and/or Steviol glycoside precursors in vivo. 
See Example 2. 
0092. In some embodiments, a recombinant host com 
prises a nucleic acid encoding a UGT85C2 polypeptide, a 
nucleic acid encoding a UGT76G1 polypeptide, a nucleic 
acid encoding a UGT74G1 polypeptide, a nucleic acid 
encoding a UGT91D2 polypeptide, and/or a nucleic acid 
encoding a EUGT11 polypeptide. The skilled worker will 
appreciate that expression of these genes may be necessary 
to produce a particular Steviol glycoside but that one or more 
of these genes can be endogenous to the host provided that 
at least one (and in some embodiments, all) of these genes 
is a recombinant gene introduced into the microorganism. In 
a particular embodiment, a Steviol-producing recombinant 
microorganism comprises exogenous nucleic acids encoding 
UGT85C2, UGT76G1, or UGT91D2 polypeptides. In 
another particular embodiment, a Steviol-producing recom 
binant microorganism comprises exogenous nucleic acids 
encoding UGT85C2, UGT76G1, UGT74G1, and UGT91D2 
polypeptides. In yet another particular embodiment, a ste 
viol-producing recombinant microorganism comprises 
exogenous nucleic acids encoding UGT85C2, UGT76G1. 
UGT74G1, and EUGT11 polypeptides. In yet another par 
ticular embodiment, a Steviol-producing recombinant micro 
organism comprises the exogenous nucleic acids encoding 
UGT85C2, UGT76G1, UGT74G1, UGT91D2 (including 
inter alia 91D2e, 91D2m, 91D2e-b, and functional 
homologs thereof), and EUGT11 polypeptides. See Example 
2 
0093. In certain embodiments, the steviol glycoside is 
RebA, RebB, RebD, and/or RebM. Reb Acan be synthesized 
in a Steviol-producing recombinant microorganism express 
ing UGT85C2, UGT76G1, UGT74G1, and UGT91D2. 
RebB can be synthesized in a steviol-producing recombinant 
microorganism expressing UGT85C2, UGT76G1, and 
UGT91D2. RebD can be synthesized in a steviol-producing 
recombinant microorganism expressing UGT85C2, 
UGT76G1 UGT74G1, and UGT91D2 and/or EUGT11. 
RebM can be synthesized in a steviol-producing recombi 
nant microorganism expressing UGT85C2, UGT76G1. 
UGT74G1, and UGT91D2 and/or EUGT11 (see FIG. 1, 
Example 2). 
0094. In some embodiments, steviol glycosides and/or 
Steviol glycoside precursors are produced through contact of 
a Steviol glycoside precursor with one or more enzymes 
involved in the steviol glycoside pathway in vitro. For 
example, contacting Steviol with a UGT polypeptide can 
result in production of a Steviol glycoside in vitro. In some 
embodiments, a Steviol glycoside precursor is produced 
through contact of an upstream Steviol glycoside precursor 
with one or more enzymes involved in the Steviol glycoside 
pathway in vitro. For example, contacting ent-kaurenoic 
acid with a KAH enzyme can result in production of steviol 
in vitro. 
0095. In some embodiments, a steviol glycoside or ste 
viol glycoside precursor is produced by whole cell biocon 
version. For whole cell bioconversion to occur, a host cell 
expressing one or more enzymes involved in the Steviol 
glycoside pathway takes up and modifies a Steviol glycoside 
precursor in the cell; following modification in Vivo, a 
Steviol glycoside remains in the cell and/or is excreted into 
the culture medium. For example, a host cell expressing a 
gene encoding a UGT polypeptide can take up Steviol and 
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glycosylate Steviol in the cell; following glycosylation in 
Vivo, a Steviol glycoside can be excreted into the culture 
medium. In some embodiments, the cell is permeabilized to 
take up a substrate to be modified or to excrete a modified 
product. 
0096. In some embodiments, a steviol glycoside or ste 
viol glycoside precursor composition produced in Vivo, in 
vitro, or by whole cell bioconversion comprises less con 
taminants than a Stevia extract from, interalia, a Stevia plant. 
Contaminants include plant-derived compounds that con 
tribute to off-flavors. Potential contaminants include pig 
ments, lipids, proteins, phenolics, Saccharides, spathulenol 
and other sesquiterpenes, labdane diterpenes, monoterpenes, 
decanoic acid, 8,11,14-eicosatrienoic acid, 2-methyloctade 
cane, pentacosane, octacosane, tetracosane, octadecanol, 
Stigmasterol, B-sitosterol, C- and B-amyrin, lupeol, B-amryin 
acetate, pentacyclic triterpenes, centauredin, quercitin, epi 
alpha-cadinol, carophylienes and derivatives, beta-pinene, 
beta-sitosterol, and gibberellin. 
0097. As used herein, the terms “detectable amount.” 
“detectable concentration,” “measurable amount,” and 
“measurable concentration” refer to a level of Steviol gly 
cosides measured in AUC. LM/ODoo, mg/L, LLM, or mM. 
Steviol glycoside production (i.e., total, Supernatant, and/or 
intracellular steviol glycoside levels) can be detected and/or 
analyzed by techniques generally available to one skilled in 
the art, for example, but not limited to, liquid chromatog 
raphy-mass spectrometry (LC-MS), thin layer chromatog 
raphy (TLC), high-performance liquid chromatography 
(HPLC), ultraviolet-visible spectroscopy/spectrophotometry 
(UV-Vis), mass spectrometry (MS), and nuclear magnetic 
resonance spectroscopy (NMR). 
0098. As used herein, the terms “or' and “and/or is 
utilized to describe multiple components in combination or 
exclusive of one another. For example, “x, y, and/or z can 
refer to 'x' alone, “y” alone. “Z” alone, “x, y, and Z.” “(x and 
y) or Z.” “x or (y and Z), or “X or y or Z.” In some 
embodiments, “and/or is used to refer to the exogenous 
nucleic acids that a recombinant cell comprises, wherein a 
recombinant cell comprises one or more exogenous nucleic 
acids selected from a group. In some embodiments, “and/or 
is used to refer to production of Steviol glycosides and/or 
Steviol glycoside precursors. In some embodiments, “and/ 
or is used to refer to production of steviol glycosides, 
wherein one or more Steviol glycosides are produced. In 
some embodiments, “and/or” is used to refer to production 
of Steviol glycosides, wherein one or more Steviol glyco 
sides are produced through one or more of the following 
steps: culturing a recombinant microorganism, synthesizing 
one or more Steviol glycosides in a recombinant microor 
ganism, and/or isolating one or more Steviol glycosides. 
Transporters and Transcription Factor Expression 
0099. This document describes reagents and methods that 
can be used to efficiently produce Steviol glycoside compo 
sitions. Modification of transport systems in a recombinant 
host that are involved in transport of Steviol glycosides into 
culture medium can allow more effective production of 
Steviol glycosides in recombinant hosts. 
0100. As set forth herein, recombinant cells having modi 
fications to cellular transport are capable of producing 
Steviol. Recombinant hosts described herein can produce 
Steviol and have altered expression of at least one endog 
enous transporter gene. Recombinant hosts described herein 
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can produce Steviol and have altered expression of a tran 
Scription factor that regulates expression of at least one 
endogenous transporter gene. Altering expression of endog 
enous transporter genes can be useful for increasing pro 
duction of Steviol and/or excretion of Steviol into the culture 
medium. 
0101. As set forth herein, recombinant cells having modi 
fications to cellular transport are capable of producing at 
least one Steviol glycoside, including, but not limited to, 
RebA, RebB, RebD, and/or RebM. Recombinant hosts 
described herein can produce at least one Steviol glycoside 
such as RebA, RebB, RebD, and/or RebM and have altered 
expression of at least one endogenous transporter gene. 
Recombinant hosts described herein can produce at least one 
Steviol glycoside such as RebA, RebB, RebD, and/or RebM 
and have altered expression of a transcription factor that 
regulates expression of at least one endogenous transporter 
gene. Recombinant hosts described herein can produce at 
least one steviol glycoside such as RebA, RebB, RebD, 
and/or RebM and have altered expression of a plurality of 
endogenous transporter genes and/or of a plurality of tran 
Scription factor genes that regulate expression of a plurality 
of endogenous transporter genes. Altering expression of 
endogenous transporter genes and/or transcription factors 
regulating expression of at least one transporter gene can be 
useful for increasing production of Steviol glycosides and/or 
excretion of Steviol glycosides into the culture medium. 
0102 Recombinant hosts disclosed herein can include 
one or more biosynthesis genes, Such as one or more genes 
encoding a Sucrose transporter and a Sucrose synthase; a 
gene encoding a geranylgeranyl diphosphate synthase (GG 
PPS) polypeptide; a gene encoding an ent-copalyl diphos 
phate synthase (CDPS) polypeptide; a gene encoding a 
kaurene synthase (KS) polypeptide; a gene encoding a 
kaurene oxidase (KO) polypeptide; a gene encoding a ste 
viol synthase (KAH) polypeptide; a gene encoding a 
cytochrome P450 reductase (CPR) polypeptide; a gene 
encoding a UGT85C2 polypeptide; a gene encoding a 
UGT76G1 polypeptide; a gene encoding a UGT74G1 poly 
peptide; a gene encoding a UGT91D2 functional homolog; 
and/or a gene encoding a EUGT11 polypeptide; wherein 
expression of one or more of these genes results in produc 
tion of steviol steviol glycosides such as RebA, RebB, 
RebD, and/or RebM. 
0103) As used herein, the terms “transport of a steviol 
glycoside,” “steviol glycoside transport,” “excretion of a 
Steviol glycoside,” and 'steviol glycoside excretion' can be 
used interchangeably. 
0104. As used herein, the term “transporter' (also 
referred to as a membrane transport protein) refers to a 
membrane protein involved in the movement of small mol 
ecules, macromolecules (such as carbohydrates), and ions 
across a biological membrane. Transporters span the mem 
brane in which they are localized and across which they 
transport Substances. Transporter proteins can assist in the 
movement (i.e., transport or excretion) of a Substance from 
the intracellular space to the culture medium. Transporters 
are known to function as passive transport systems, carrying 
molecules down their concentration gradient, or as active 
transport systems, using energy to carry molecules uphill 
against their concentration gradient. Active transport is 
mediated by carriers which couple transport directly to the 
use of energy derived from hydrolysis of an ATP molecule 
or by carriers which make use of a pre-established electro 
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chemical ion gradient to drive co-transport of the nutrient 
molecule and a co-transported ion. The latter category 
comprises Symporters and antiporters, which carry the ion in 
the same or opposite direction, respectively, as the trans 
ported substrate. 
0105 Transport proteins have been classified according 
to various criteria at the Transporter Classification Database 
(on the world wide web at tcdb.org). See, Saier Jr. et al., 
Nucl. Acids Res., 42(1): D251-258 (2014). Non-limiting 
examples thereof include, among others, the family of 
Multiple Drug Resistance (MDR) plasma membrane trans 
porters that is thought to be ubiquitous among living organ 
isms. The MDR transporter superfamily can be further 
subdivided according to the mode of operation by which the 
substrate is transported from one side of the membrane to the 
other. Transporters can operate to move Substances across 
membranes in response to chemiosmotic ion gradients or by 
active transport. ATP-binding cassette transporters (ABC 
transporters) are transmembrane proteins that utilize the 
energy of adenosine triphosphate (ATP) hydrolysis to carry 
out translocation of various Substrates across membranes. 
They can transport a wide variety of Substrates across the 
plasma membrane and intracellular membranes, including 
metabolic products, lipids and sterols, and drugs. Particular 
non-limiting examples of endogenous ABC transporter 
genes include PDR5, YDR061W, PDR15, SNO2, YOR1, 
YOLO75C, MDL2, ADP1, CAF16, VMR1 and STE6 (or a 
functional homolog thereof). In some aspects, ABC trans 
porters transport Steviol glycosides. 
0106 A second group of MDRs is further subdivided 
based on the nature of the chemiosmotic gradient that 
facilitates the transport. Saier, Jr. et al., J. Mol. Microbiol. 
Biotechnol. 1:257-279 (1999). In some aspects, MDR trans 
porters transport Steviol glycosides. 
0107 Another transporter family, the Major Facilitator 
Superfamily (MFS) transporters are monomeric polypep 
tides that can transport Small solutes in response to proton 
gradients. The MFS transporter family is sometimes referred 
to as the uniporter-symporter-antiporter family. MFS trans 
porters function in, interalia, in Sugar uptake and drug efflux 
systems. MFS transporters typically comprise conserved 
MFS-specific motifs. Non-limiting examples of endogenous 
MFS transporter genes include DTR1, SEO1, YBR241C, 
VBA3, FEN2, SNF3, STL1, HXT10, AZR1, MPH3, VBA5, 
GEX2, SNO1, AQR1, MCH1, MCH5, ATG22, HXT15, 
MPH2, ITR1, SIT1, VPS73, HXT5, QDR1, QDR2, QDR3, 
SOA1, HXT9, YMR279C, YIL166C, HOL1, ENB1, TPO4 
and FLR1 (or a functional homolog thereof). In some 
aspects, MFS transporters transport Steviol glycosides. 
0108. Other transporter families include the SMR (small 
multidrug resistant) family, RND (Resistance-Nodulation 
Cell Division) family, and the MATE (multidrug and toxic 
compound extrusion) family. The SMR family members are 
integral membrane proteins characterized by four alpha 
helical transmembrane Strands that confer resistance to a 
broad range of antiseptics, lipophilic quaternary ammonium 
compounds (QAC), and aminoglycoside resistance in bac 
teria. See, Bay & Turner, 2009, BMC Evol Biol. 9:140. In 
Some aspects, SMR transporters transport Steviol glycosides. 
0109. The MATE family members comprise 12 trans 
membrane (TM) domains. Members of the MATE family 
have been identified in prokaryotes, yeast Such as S. cerevi 
siae and Schizosaccharomyces pombe, and plants. See 
Diener et al., 2001, Plant Cell. 13(7):1625-8. The MATE 
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family members are sodium or proton antiporters. In some 
aspects, MATE transporters transport Steviol glycosides. 
0110. Additional transporter families include the amino 
acid/auxin permease (AAAP) family (for example, 
YKL146W/AVT3, YBL089W/AVT5, YER119C/AVT6 and 
YIL088C/AVT7), the ATPase family (for example, 
YBL099W/ATP1, YDL185W/VMA1, YLR447C/VMA6, 
YOLO77W/ATP19, YPL078C/ATP4, YEL027W/VMA3, 
YKL016C/ATP7, and YOR332W/VMA4), the sulfate per 
mease (SulP) family (for example, YBR294W/SUL1, 
YGR125W and YPR003C), the lysosomal cystine trans 
porter (LCT) family (for example, YCR075C/ERS1), the 
Ca2+:cation antiporter (CaCA) family (for example, 
YDL128W/VCX1 and YJR106W/ECM27), the amino acid 
polyamine-organocation (APC) Superfamily (for example, 
YDL210W/UGA4, YOLO2OW/TAT2, YPL274W/SAM3, 
YNL268W/LYP1, YHL036W/MUP3, YKRO39W/GAP1 
and YOR348C/PUT4), multidrug/oligosaccharidyl-lipid/ 
polysaccharide (MOP) (for example, YDR338C), the ZRT/ 
IRT-like protein (ZIP) metal transporter family (for example, 
YGL225W/ZRT1 and YOR079C/ATX2), the mitochondrial 
protein translocase (MPT) family (for example, YGR181 W/ 
TIM13, YNL07OW/TOM7, YNL121C/TOM70, the voltage 
gated ion channel (VIC) family (for example, YGR217W/ 
CCH1 and YJL093C/TOK1), the monovalent cation: proton 
antiporter-2 (CPA2) family (for example, YJL094C/KHA1), 
the ThrE family of putative transmembrane amino acid 
efflux transporters (for example, YJL108C/PRM10), the 
oligopeptide transporter (OPT) family (for example, 
YJL212C/OPT1 and YGL114W), the K" transporter (Trk) 
family (for example, TKR050W/TRK2), the bile acid:Na 
symporter (BASS) family (for example, YMR034C), the 
drug/metabolite transporter (DMT) superfamily (for 
example, YMR253C, YML038C/YMD8, and YOR307C/ 
SLY41), the mitochondrial carrier (MC) family (for 
example, YMR056C/AAC1, YNL083 W/SAL1, YOR130C/ 
ORT1, YOR222W/ODC2, YPR011C, YPRO58W/YMC1, 
YMR166C, YNL003C/PET8 and YOR100C/CRC1), the 
auxin efflux carrier (AEC) family (for example, YNL095C, 
YOR092W/ECM3 and YBR287W), the ammonia channel 
transporter (Amt) family (for example, YNL142W/MEP2), 
the metal ion (Mn"-iron) transporter (Nramp) family (for 
example, YOL122C/SMF1), the transient receptor potential 
Ca" channel (TRP-CC) family (for example, YOR087W/ 
YVC1), the arsenical resistance-3 (ACR3) family (for 
example, YPR201W/ARR3), the nucleobase:cation sym 
porter-1 (NCS1) family (for example, YBR021 W/FUR4), 
the inorganic phosphate transporter (PiT) family (for 
example, YBR296C/PHO089), the arsenite-antimonite (Ar 
SAB) efflux family (for example, YDL100C/GET3), the 
IISP family of transporters, the glycerol uptake (GUP) 
family (for example, YGL084C/GUP1), the metal ion trans 
port (MIT) family (for example, YKL064W/MNR2, 
YKL050C and YOR334W/MRS2), the copper transport 
(Ctr) family (for example, YLR411 W/CTR3) and the cation 
diffusion facilitator (CDF) family (for example, YOR316C/ 
COT1). Particular members of any of these transporter 
families are included within the scope of the disclosed 
invention to the extent that altered expression in a cell 
capable of producing Steviol glycoside increases production 
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of said steviol glycoside from the cell; exemplary members 
are disclosed above and in Tables 5, 6, and 14. 
0111. As used herein, the term “transcription factor 
refers to a DNA-binding protein that regulates gene expres 
Sion. Preferably, the transcription factor regulates expression 
of at least one transporter gene. 
0112 Methods for identifying a gene affecting produc 
tion or transport of Steviol glycosides and Steviol glycoside 
pathway intermediates are disclosed herein. Such methods 
can involve inactivating at least one endogenous transporter 
gene or modifying expression of at least one transporter 
gene. Typically, a library of mutant microorganisms is 
prepared, each mutant in the library having a different 
endogenous transporter gene inactivated. Methods of inac 
tivating genes and determining their effect in a microorgan 
isms are known to a person having ordinary skill in the art; 
additional methods are disclosed in WO 2014/122328, the 
disclosure of which is incorporated by reference in its 
entirety. The mutant microorganisms comprising one or 
more Steviol glycoside pathway genes are cultured in a 
medium under conditions in which steviol or a steviol 
glycoside is synthesized, and the amount of total, Superna 
tant, and/or intracellular Steviol glycosides produced by the 
microorganism is measured (e.g., using LC-MS) as 
described herein. 
0113. The disclosure is directed to recombinant host cells 
in which expression of endogenous transporter or transcrip 
tion factor genes is modified. In some embodiments, the 
transporter or transcription factor gene is endogenous to S. 
cerevisiae, including, but not limited to S. cerevisiae strain 
S288C. In some embodiments, expression of an endogenous 
transporter or transcription factor can be modified by replac 
ing the endogenous promoter with a different promoter that 
results in increased expression of the transporter protein 
(e.g., at least a 5% increase in expression, Such as at least a 
10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50%, 
100%, 200% increase or more in expression). For example, 
an endogenous promoter can be replaced with a constitutive 
or inducible promoter that results in increased expression of 
the transporter. Homologous recombination can be used to 
replace the promoter of an endogenous gene with a different 
promoter that results in increased expression of the trans 
porter. In other embodiments, the inducible or constitutive 
promoter and endogenous transporter or transcription factor 
can be integrated into another locus of the genome using 
homologous recombination. In other embodiments, the 
transporter or transcription factor gene can be introduced 
into a microorganism using exogenous plasmids with a 
promoter that results in overexpression of the transporter or 
transcription factor in the microorganism. In yet another 
embodiment, the exogenous plasmids may also comprise 
multiple copies of the transporter or transcription factor 
gene. In a further embodiment, the endogenous transporter 
or transcription factor can be induced to be overexpressed 
using native mechanisms to the recombinant microorganism 
(e.g. heat shock, stress, heavy metal, or antibiotic exposure). 
In yet a further embodiment, the activity of an endogenous 
gene product is enhanced or increased (for example, by 
mutation). In yet another embodiment, a homologous or 
orthologous gene of an endogenous yeast transporter or 
transcription factor gene is overexpressed. 
0114. In certain other embodiments, modified expression 
of a target gene in a recombinant microorganism comprises 
overexpressing a transporter gene and/or a transcription 
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NO:44, YJR106W of SEQ ID NO:48, and YMR166C of 
SEQID NO:132 improves excretion and/or total production 
of RebD, and YBR043C of SEQ ID NO:88, YEL027W of 
SEQID NO:102, YIL166C (SEQ ID NO:121), YJL093C of 
SEQ ID NO:44, YJR106W of SEQ ID NO:48, and 
YMR166C of SEQ ID NO:132 improves excretion and/or 
total production of RebM, as measured by an increase in 
RebD and RebM levels in the supernatant compared to a 
control Steviol glycoside-producing strain. See Example 6. 
0122. In some embodiments, Steviol glycoside-producing 
S. cerevisiae strains overexpressing YJL093C (SEQ ID 
NO:44) or YBR043C (SEQ ID NO:88) produce higher 
levels of RebD+RebM, compared to a steviol glycoside 
producing S. cerevisiae strain that does not overexpress 
YJL093C or YBR043C. See Example 7. 
0123. In some embodiments, a transporter that is knocked 
out can also have specificity for transport of larger molecular 
weight steviol glycosides (for example, RebD and the 
knockout of YGR181W of SEQID NO:38 or YOR291W of 
SEQID NO:74), and therefore, can be useful to overexpress 
in strains where transport of RebD into the culture medium 
is desired. With appropriate balancing of the rate of glyco 
Sylation activity through expression of pathway UGTs, 
Smaller molecular weight Steviol glycosides are further 
glycosylated before they are transported into the culture 
medium. For example, higher expression levels of a 
UGT76G1 and UGT91D2e and/or EUGT11, as compared to 
the UGT74G1 and UGT85C2 enzymes, can prevent accu 
mulation of the Steviol monoglucosides that are transported 
more readily. If the UGT activity level is higher (so the 
glycosylation rate is faster) than the rate of transport, then 
greater amounts of larger molecular weight Steviol glyco 
sides will be produced. 
Steviol and Steviol Glycoside Biosynthesis Nucleic Acids 
0124. A recombinant gene encoding a polypeptide 
described herein comprises the coding sequence for that 
polypeptide, operably linked in sense orientation to one or 
more regulatory regions suitable for expressing the poly 
peptide. Because many microorganisms are capable of 
expressing multiple gene products from a polycistronic 
mRNA, multiple polypeptides can be expressed under the 
control of a single regulatory region for those microorgan 
isms, if desired. A coding sequence and a regulatory region 
are considered to be operably linked when the regulatory 
region and coding sequence are positioned so that the 
regulatory region is effective for regulating transcription or 
translation of the sequence. Typically, the translation initia 
tion site of the translational reading frame of the coding 
sequence is positioned between one and about fifty nucleo 
tides downstream of the regulatory region for a monocis 
tronic gene. 
0125. In many cases, the coding sequence for a polypep 
tide described herein is identified in a species other than the 
recombinant host, i.e., is a heterologous nucleic acid. Thus, 
if the recombinant host is a microorganism, the coding 
sequence can be from other prokaryotic or eukaryotic micro 
organisms, from plants or from animals. In some case, 
however, the coding sequence is a sequence that is native to 
the host and is being reintroduced into that organism. A 
native sequence can often be distinguished from the natu 
rally occurring sequence by the presence of non-natural 
sequences linked to the exogenous nucleic acid, e.g., non 
native regulatory sequences flanking a native sequence in a 
recombinant nucleic acid construct. In addition, stably trans 
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formed exogenous nucleic acids typically are integrated at 
positions other than the position where the native sequence 
is found. "Regulatory region” refers to a nucleic acid having 
nucleotide sequences that influence transcription or transla 
tion initiation and rate, and stability and/or mobility of a 
transcription or translation product. Regulatory regions 
include, without limitation, promoter sequences, enhancer 
sequences, response elements, protein recognition sites, 
inducible elements, protein binding sequences, 5' and 3' 
untranslated regions (UTRs), transcriptional start sites, ter 
mination sequences, polyadenylation sequences, introns, 
and combinations thereof. A regulatory region typically 
comprises at least a core (basal) promoter. A regulatory 
region also may include at least one control element, such as 
an enhancer sequence, an upstream element or an upstream 
activation region (UAR). A regulatory region is operably 
linked to a coding sequence by positioning the regulatory 
region and the coding sequence so that the regulatory region 
is effective for regulating transcription or translation of the 
sequence. For example, to operably link a coding sequence 
and a promoter sequence, the translation initiation site of the 
translational reading frame of the coding sequence is typi 
cally positioned between one and about fifty nucleotides 
downstream of the promoter. A regulatory region can, how 
ever, be positioned as much as about 5,000 nucleotides 
upstream of the translation initiation site, or about 2,000 
nucleotides upstream of the transcription start site. 
0.126 The choice of regulatory regions to be included 
depends upon several factors, including, but not limited to, 
efficiency, selectability, inducibility, desired expression 
level, and preferential expression during certain culture 
stages. It is a routine matter for one of skill in the art to 
modulate the expression of a coding sequence by appropri 
ately selecting and positioning regulatory regions relative to 
the coding sequence. It will be understood that more than 
one regulatory region may be present, e.g., introns, enhanc 
ers, upstream activation regions, transcription terminators, 
and inducible elements. 
I0127. One or more genes can be combined in a recom 
binant nucleic acid construct in "modules' useful for a 
discrete aspect of Steviol and/or Steviol glycoside produc 
tion. Combining a plurality of genes in a module, particu 
larly a polycistronic module, facilitates the use of the 
module in a variety of species. For example, a Steviol 
biosynthesis gene cluster, or a UGT gene cluster, can be 
combined in a polycistronic module Such that, after insertion 
of a suitable regulatory region, the module can be introduced 
into a wide variety of species. As another example, a UGT 
gene cluster can be combined Such that each UGT coding 
sequence is operably linked to a separate regulatory region, 
to form a UGT module. Such a module can be used in those 
species for which monocistronic expression is necessary or 
desirable. In addition to genes useful for Steviol or steviol 
glycoside production, a recombinant construct typically also 
comprises an origin of replication, and one or more select 
able markers for maintenance of the construct in appropriate 
species. 
I0128. It will be appreciated that because of the degen 
eracy of the genetic code, a number of nucleic acids can 
encode a particular polypeptide; i.e., for many amino acids, 
there is more than one nucleotide triplet that serves as the 
codon for the amino acid. Thus, codons in the coding 
sequence for a given polypeptide can be modified Such that 
optimal expression in a particular host is obtained, using 
appropriate codon bias tables for that host (e.g., microor 
ganism). As isolated nucleic acids, these modified sequences 
can exist as purified molecules and can be incorporated into 
a vector or a virus for use in constructing modules for 
recombinant nucleic acid constructs. 
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0129. In some cases, it is desirable to inhibit one or more 
functions of an endogenous polypeptide in order to divert 
metabolic intermediates towards Steviol or steviol glycoside 
biosynthesis. For example, it may be desirable to downregu 
late synthesis of sterols in a strain in order to further increase 
Steviol or Steviol glycoside production, e.g., by downregu 
lating squalene epoxidase. As another example, it may be 
desirable to inhibit degradative functions of certain endog 
enous gene products, e.g., glycohydrolases that remove 
glucose moieties from secondary metabolites or phos 
phatases as discussed herein. As another example, expres 
sion of membrane transporters involved in transport of 
Steviol glycosides can be activated, such that transportation 
of Steviol glycosides is increased. Such regulation can be 
beneficial in that transportation of Steviol glycosides can be 
increased for a desired period of time during culture of the 
microorganism, thereby increasing the yield of glycoside 
product(s) at harvest. In Such cases, a nucleic acid that 
overexpresses the polypeptide or gene product may be 
included in a recombinant construct that is transformed into 
the strain. Alternatively, mutagenesis can be used to generate 
mutants in genes for which it is desired to increase or 
enhance function. 
Recombinant Hosts 
0130 Recombinant hosts can be used to express poly 
peptides for the producing Steviol glycosides, including 
mammalian, insect, plant, and algal cells. A number of 
prokaryotes and eukaryotes are also suitable for use in 
constructing the recombinant microorganisms described 
herein, e.g., gram-negative bacteria, yeast, and fungi. A 
species and strain selected for use as a steviol glycoside 
production strain is first analyzed to determine which pro 
duction genes are endogenous to the strain and which genes 
are not present. Genes for which an endogenous counterpart 
is not present in the strain are advantageously assembled in 
one or more recombinant constructs, which are then trans 
formed into the strain in order to Supply the missing function 
(s). 
0131 Typically, the recombinant microorganism is 
grown in a fermenter at a defined temperature(s) for a 
desired period of time. The constructed and genetically 
engineered microorganisms provided by the invention can 
be cultivated using conventional fermentation processes, 
including, inter alia, chemostat, batch, fed-batch cultiva 
tions, semi-continuous fermentations such as draw and fill, 
continuous perfusion fermentation, and continuous perfu 
sion cell culture. Depending on the particular microorgan 
ism used in the method, other recombinant genes such as isopentenyl biosynthesis genes and terpene synthase and 
cyclase genes may also be present and expressed. Levels of 
Substrates and intermediates, e.g., isopentenyl diphosphate, 
dimethylallyl diphosphate, GGPP. kaurene and kaurenoic 
acid, can be determined by extracting samples from culture 
media for analysis according to published methods. 
0132 Carbon sources of use in the instant method include 
any molecule that can be metabolized by the recombinant 
host cell to facilitate growth and/or production of the steviol 
glycosides. Examples of Suitable carbon Sources include, but 
are not limited to. Sucrose (e.g., as found in molasses), 
fructose, Xylose, ethanol, glycerol, glucose, cellulose, starch, 
cellobiose or other glucose-comprising polymer. In embodi 
ments employing yeast as a host, for example, carbon 
Sources such as Sucrose, fructose, Xylose, ethanol, glycerol, 
and glucose are suitable. The carbon source can be provided 
to the host organism throughout the cultivation period or 
alternatively, the organism can be grown for a period of time 
in the presence of another energy source, e.g., protein, and 
then provided with a source of carbon only during the 
fed-batch phase. 
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I0133. After the recombinant microorganism has been 
grown in culture for the desired period of time, Steviol 
and/or one or more Steviol glycosides can then be recovered 
from the culture using various techniques known in the art. 
In some embodiments, a permeabilizing agent can be added 
to aid the feedstock entering into the host and product 
getting out. For example, a crude lysate of the cultured 
microorganism can be centrifuged to obtain a Supernatant. 
The resulting Supernatant can then be applied to a chroma 
tography column, e.g., a C-18 column, and washed with 
water to remove hydrophilic compounds, followed by elu 
tion of the compound(s) of interest with a solvent such as 
methanol. The compound(s) can then be further purified by 
preparative HPLC. See also, WO 2009/140394. 
I0134. It will be appreciated that the various genes and 
modules discussed herein can be present in two or more 
recombinant hosts rather than a single host. When a plurality 
of recombinant hosts is used, they can be grown in a mixed 
culture to produce Steviol and/or Steviol glycosides. 
0.135 Alternatively, the two or more hosts each can be 
grown in a separate culture medium and the product of the 
first culture medium, e.g., Steviol, can be introduced into 
second culture medium to be converted into a Subsequent 
intermediate, or into an end product such as, for example, 
RebA. The product produced by the second, or final host is 
then recovered. It will also be appreciated that in some 
embodiments, a recombinant host is grown using nutrient 
Sources other than a culture medium and utilizing a system 
other than a fermenter. 
0.136 Exemplary prokaryotic and eukaryotic species are 
described in more detail below. However, it will be appre 
ciated that other species can be suitable. For example, 
Suitable species can be in a genus Such as Agaricus, Asper 
gillus, Bacillus, Candida, Corynebacterium, Eremothecium, 
Escherichia, Fusarium/Gibberella, Kluyveromyces, Laeti 
porus, Lentinus, Phafia, Phanerochaete, Pichia, Physcomi 
trella, Rhodoturula, Saccharomyces, Schizosaccharomyces, 
Sphacelona, Xanthophyllomyces or Yarrowia. Exemplary 
species from Such genera include Lentinus tigrinus, Laeti 
porus sulphureus, Phanerochaete chrysosporium, Pichia 
pastoris, Cyberlindnera jadinii, Physcomitrella patens, Rho 
doturula glutinis, Rhodoturula mucilaginosa, Phafia rho 
dozyma, Xanthophyllomyces dendrorhous, Fusarium fitjik 
uroi/Gibberellafiujikuroi, Candida utilis, Candida glabrata, 
Candida albicans, and Yarrowia lipolytica. 
0.137 In some embodiments, a microorganism can be a 
prokaryote such as Escherichia coli. 
0.138. In some embodiments, a microorganism can be an 
Ascomycete Such as Gibberella filiikuroi, Kluyveromyces 
lactis, Schizosaccharomyces pombe, Aspergillus niger, Yar 
rowia lipolytica, Ashbya gossypil, or S. cerevisiae. 
0.139. In some embodiments, a microorganism can be an 
algal cell Such as Blakeslea trispora, Dunaliella salina, 
Haematococcus pluvialis, Chlorella sp., Undaria pinnati 
fida, Sargassum, Laminaria japonica, Scenedesmus almer 
iensis species. 
0140. In some embodiments, a microorganism can be a 
cyanobacterial cell Such as Blakeslea trispora, Dunaliella 
salina, Haematococcus pluvialis, Chlorella sp., Undaria 
pinnatifida, Sargassum, Laminaria japonica, Scenedesmus 
almeriensis. 
Saccharomyces spp. 
0141 Saccharomyces is a widely used chassis organism 
in synthetic biology, and can be used as the recombinant 
microorganism platform. For example, there are libraries of 
mutants, plasmids, detailed computer models of metabolism 
and other information available for S. cerevisiae, allowing 
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for rational design of various modules to enhance product 
yield. Methods are known for making recombinant micro 
organisms. 
Aspergillus spp. 
0142 Aspergillus species such as A. Oryzae, A. niger and 
A. Sojae are widely used microorganisms in food production 
and can also be used as the recombinant microorganism 
platform. Nucleotide sequences are available for genomes of 
A. nidulans, A. fumigatus, A. Oryzae, A. clavatus, A. flavus, 
A. niger, and A. terreus, allowing rational design and modi 
fication of endogenous pathways to enhance flux and 
increase product yield. Metabolic models have been devel 
oped for Aspergillus, as well as transcriptomic studies and 
proteomics studies. A. niger is cultured for the industrial 
production of a number of food ingredients such as citric 
acid and gluconic acid, and thus species such as A. niger are 
generally Suitable for producing Steviol glycosides. 
E. coli 
0143 E. coli, another widely used platform organism in 
synthetic biology, can also be used as the recombinant 
microorganism platform. Similar to Saccharomyces, there 
are libraries of mutants, plasmids, detailed computer models 
of metabolism and other information available for E. coli, 
allowing for rational design of various modules to enhance 
product yield. Methods similar to those described above for 
Saccharomyces can be used to make recombinant E. coli 
microorganisms. 
0144. Agaricus, Gibberella, and Phanerochaete spp. 
0145 Agaricus, Gibberella, and Phanerochaete spp. can 
be useful because they are known to produce large amounts 
of isoprenoids in culture. Thus, the terpene precursors for 
producing large amounts of Steviol glycosides are already 
produced by endogenous genes. Thus, modules comprising 
recombinant genes for Steviol glycoside biosynthesis poly 
peptides can be introduced into species from Such genera 
without the necessity of introducing mevalonate or MEP 
pathway genes. 
Arxula adeninivorans (Blastobotry's adeninivorans) 
0146 Arxula adeninivorans is dimorphic yeast (it grows 
as budding yeast like the baker's yeast up to a temperature 
of 42° C., above this threshold it grows in a filamentous 
form) with unusual biochemical characteristics. It can grow 
on a wide range of Substrates and can assimilate nitrate. It 
has successfully been applied to the generation of strains 
that can produce natural plastics or the development of a 
biosensor for estrogens in environmental samples. 
Yarrowia lipolytica 
0147 Yarrowia lipolytica is dimorphic yeast (see Arxula 
adeninivorans) and belongs to the family Hemiascomycetes. 
The entire genome of Yarrowia lipolytica is known. Yar 
rowia species is aerobic and considered to be non-patho 
genic. Yarrowia is efficient in using hydrophobic Substrates 
(e.g. alkanes, fatty acids, oils) and can grow on Sugars. It has 
a high potential for industrial applications and is an oleagi 
nous microorganism. Yarrowia lipolyptica can accumulate 
lipid content to approximately 40% of its dry cell weight and 
is a model organism for lipid accumulation and remobiliza 
tion. See e.g., Nicaud, 2012, Yeast 29(10):409-18; Beopou 
los et al., 2009, Biohimie 91(6):692-6: Bankar et al., 2009, 
Appl Microbiol Biotechnol. 84(5):847-65. 
Rhodotorula sp. 
0148 Rhodotorula is unicellular, pigmented yeast. The 
oleaginous red yeast, Rhodotorula glutinis, has been shown 
to produce lipids and carotenoids from crude glycerol 
(Saenge et al., 2011, Process Biochemistry 46(1):210-8). 
Rhodotorula toruloides strains have been shown to be an 
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efficient fed-batch fermentation system for improved bio 
mass and lipid productivity (Li et al., 2007, Enzyme and 
Microbial Technology 41:312-7). 
0149 Rhodosporidium toruloides 
0150 Rhodosporidium toruloides is oleaginous yeast and 
useful for engineering lipid-production pathways (See e.g. 
Zhu et al., 2013, Nature Commun. 3:1112: Ageitos et al., 
2011, Applied Microbiology and Biotechnology 90(4): 1219 
27). 
Candida boidinii 
0151 Candida boidinii is methylotrophic yeast (it can 
grow on methanol). Like other methylotrophic species Such 
as Hansenula polymorpha and Pichia pastoris, it provides 
an excellent platform for producing heterologous proteins. 
Yields in a multigram range of a secreted foreign protein 
have been reported. A computational method, IPRO, 
recently predicted mutations that experimentally switched 
the cofactor specificity of Candida boidinii xylose reductase 
from NADPH to NADH. See, e.g., Mattanovich et al., 2012, 
Methods Mol Biol. 824:329-58; Khoury et al., 2009, Protein 
Sci. 18(10):2125-38. 
Hansenula polymorpha (Pichia angusta) 
0152 Hansenula polymorpha is methylotrophic yeast 
(see Candida boidinii). It can furthermore grow on a wide 
range of other Substrates; it is thermo-tolerant and can 
assimilate nitrate (see also Kluyveromyces lactis). It has 
been applied to producing hepatitis B vaccines, insulin and 
interferon alpha-2a for the treatment of hepatitis C, further 
more to a range of technical enzymes. See, e.g., Xu et al., 
2014, Virol Sin. 29(6):403-9. 
Kluyveromyces lactis 
0153 Kluyveromyces lactis is yeast regularly applied to 
the production of kefir. It can grow on several Sugars, most 
importantly on lactose which is present in milk and whey. It 
has successfully been applied among others for producing 
chymosin (an enzyme that is usually present in the stomach 
of calves) for producing cheese. Production takes place in 
fermenters on a 40,000 L scale. See, e.g., van Ooyen et al., 
2006, FEMS Yeast Res. 6(3):381-92. 
Pichia pastoris 
0154 Pichia pastoris is methylotrophic yeast (see Can 
dida boidinii and Hansenula polymorpha). It provides an 
efficient platform for producing foreign proteins. Platform 
elements are available as a kit and it is worldwide used in 
academia for producing proteins. Strains have been engi 
neered that can produce complex human N-glycan (yeast 
glycans are similar but not identical to those found in 
humans). See, e.g., Piirainen et al., 2014, N Biotechnol. 
31(6):532-7. 
Physcomitrella spp. 
0155 Physcomitrella mosses, when grown in suspension 
culture, have characteristics similar to yeast or other fungal 
cultures. This genera can be used for producing plant 
secondary metabolites, which can be difficult to produce in 
other types of cells. 
Steviol Glycoside Compositions 
0156 Steviol glycosides do not necessarily have equiva 
lent performance in different food systems. It is therefore 
desirable to have the ability to direct the synthesis to steviol 
glycoside compositions of choice. Recombinant hosts 
described herein can produce compositions that are selec 
tively enriched for specific steviol glycosides (e.g., RebD) 
and have a consistent taste profile. Thus, the recombinant 
hosts described herein can facilitate the production of com 
positions that are tailored to meet the Sweetening profile 
desired for a given food product and that have a proportion 
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of each Steviol glycoside that is consistent from batch to 
batch. Hosts described herein do not produce the undesired 
plant by-products found in Stevia extracts. Thus, Steviol 
glycoside compositions produced by the recombinant hosts 
described herein are distinguishable from compositions 
derived from Stevia plants. 
0157. The amount of an individual steviol glycoside (e.g., 
RebA, RebB, RebD, or RebM) produced can be from about 
1 mg/L to about 2,800 mg/L, e.g., about 1 to about 10 mg/L. 
about 3 to about 10 mg/L, about 5 to about 20 mg/L, about 
10 to about 50 mg/L, about 10 to about 100 mg/L, about 25 
to about 500 mg/L, about 100 to about 1,500 mg/L, or about 
200 to about 1,000 mg/L, at least about 1,000 mg/L, at least 
about 1,200 mg/L, at least about at least 1,400 mg/L, at least 
about 1,600 mg/L, at least about 1,800 mg/L, or at least 
about 2,800 mg/L. In some aspects, the amount of an 
individual steviol glycoside can exceed 2,800 mg/L. The 
amount of a combination of Steviol glycosides (e.g., RebA, 
RebB, RebD, or RebM) produced can be from about 1 mg/L 
to about 6,000 mg/L, e.g., about 200 to about 1,500, at least 
about 2,000 mg/L, at least about 3,000 mg/L, at least about 
4,000 mg/L, at least about 5,000 mg/L, or at least about 
6,000 mg/L. In some aspects, the amount of a combination 
of Steviol glycosides can exceed 6,000 mg/L. In general, 
longer culture times will lead to greater amounts of product. 
Thus, the recombinant microorganism can be cultured for 
from 1 day to 7 days, from 1 day to 5 days, from 3 days to 
5 days, about 3 days, about 4 days, or about 5 days. 
0158. It will be appreciated that the various genes and 
modules discussed herein can be present in two or more 
recombinant microorganisms rather than a single microor 
ganism. When a plurality of recombinant microorganisms is 
used, they can be grown in a mixed culture to produce 
Steviol and/or Steviol glycosides. For example, a first micro 
organism can comprise one or more biosynthesis genes for 
producing Steviol and null mutations in a first group of 
endogenous transporters, while a second microorganism 
comprises Steviol glycoside biosynthesis genes and null 
mutations in a second group of endogenous transporters. The 
product produced by the second, or final microorganism is 
then recovered. It will also be appreciated that in some 
embodiments, a recombinant microorganism is grown using 
nutrient sources other than a culture medium and utilizing a 
system other than a fermenter. 
0159. Alternatively, the two or more microorganisms 
each can be grown in a separate culture medium and the 
product of the first culture medium, e.g., Steviol, can be 
introduced into second culture medium to be converted into 
a Subsequent intermediate, or into an end product Such as 
RebA. The product produced by the second, or final micro 
organism is then recovered. The microorganisms can have 
the same or a different group of mutations in endogenous 
transporters. It will also be appreciated that in some embodi 
ments, a recombinant microorganism is grown using nutri 
ent Sources other than a culture medium and utilizing a 
system other than a fermenter. 
0160 Steviol glycosides do not necessarily have equiva 
lent performance in different food systems. It is therefore 
desirable to have the ability to direct the synthesis to steviol 
glycoside compositions of choice. Recombinant hosts 
described herein can produce compositions that are selec 
tively enriched for specific steviol glycosides (e.g., RebD) 
and have a consistent taste profile. Thus, the recombinant 
microorganisms described herein can facilitate the produc 
tion of compositions that are tailored to meet the Sweetening 
profile desired for a given food product and that have a 
proportion of each Steviol glycoside that is consistent from 
batch to batch. Microorganisms described herein do not 
produce the undesired plant byproducts found in Stevia 
extracts. Thus, Steviol glycoside compositions produced by 
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the recombinant microorganisms described herein are dis 
tinguishable from compositions derived from Stevia plants. 
0.161 Steviol glycosides and compositions obtained by 
the methods disclosed herein can be used to make food 
products, dietary Supplements and Sweetener compositions. 
See, e.g., WO 2011/153378, WO 2013/022989, WO 2014/ 
122227, and WO 2014/122328, each of which has been 
incorporated by reference in its entirety. 
0162 For example, substantially pure steviol or steviol 
glycoside such as RebM or RebD can be included in food 
products such as ice cream, carbonated beverages, fruit juices, yogurts, baked goods, chewing gums, hard and Soft 
candies, and sauces. Substantially pure Steviol or Steviol 
glycoside can also be included in non-food products such as 
pharmaceutical products, medicinal products, dietary 
Supplements and nutritional Supplements. Substantially pure 
Steviol or Steviol glycosides may also be included in animal 
feed products for both the agriculture industry and the 
companion animal industry. Alternatively, a mixture of 
Steviol and/or Steviol glycosides can be made by culturing 
recombinant microorganisms separately, each producing a 
specific Steviol or Steviol glycoside, recovering the Steviol or 
Steviol glycoside in Substantially pure form from each 
microorganism and then combining the compounds to obtain 
a mixture comprising each compound in the desired propor 
tion. The recombinant microorganisms described herein 
permit more precise and consistent mixtures to be obtained 
compared to current Stevia products. For example, recom 
binant microorganisms described herein can express trans 
porters specific for transport of a particular rebaudioside into 
the culture medium. When a transporter is specific for a 
particular rebaudioside it will enrich the concentration of 
that compound in the fermentation broth, preventing it from 
being further reacted to a different compound, and by 
selectively transporting the rebaudioside into the fermenta 
tion broth it will make it easier to recover from the other 
rebaudiosides and therefore making the process more effi 
cient. 
0163. In another alternative, a substantially pure steviol 
or Steviol glycoside can be incorporated into a food product 
along with other Sweeteners, e.g. saccharin, dextrose, 
Sucrose, fructose, erythritol, aspartame, Sucralose, monatin, 
or acesulfame potassium. The weight ratio of Steviol or 
Steviol glycoside relative to other sweeteners can be varied 
as desired to achieve a satisfactory taste in the final food 
product. See, e.g., U.S. 2007/0128311. In some embodi 
ments, the steviol or steviol glycoside may be provided with 
a flavor (e.g., citrus) as a flavor modulator. 
0164 Compositions produced by a recombinant micro 
organism described herein can be incorporated into food 
products. For example, a Steviol glycoside composition 
produced by a recombinant microorganism can be incorpo 
rated into a food product in an amount ranging from about 
20 mg steviol glycoside/kg food product to about 1800 mg 
Steviol glycoside/kg food product on a dry weight basis, 
depending on the type of Steviol glycoside and food product. 
For example, a Steviol glycoside composition produced by a 
recombinant microorganism can be incorporated into a 
dessert, cold confectionary (e.g., ice cream), dairy product (e.g., yogurt), or beverage (e.g., a carbonated beverage) Such 
that the food product has a maximum of 500 mg steviol 
glycoside/kg food on a dry weight basis. A Steviol glycoside 
composition produced by a recombinant microorganism can 
be incorporated into a baked good (e.g., a biscuit) Such that 
the food product has a maximum of 300 mg Steviol glyco 
side/kg food on a dry weight basis. A Steviol glycoside 
composition produced by a recombinant microorganism can 
be incorporated into a sauce (e.g., chocolate syrup) or 
vegetable product (e.g., pickles) such that the food product 
has a maximum of 1000 mg Steviol glycoside/kg food on a 
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dry weight basis. A Steviol glycoside composition produced 
by a recombinant microorganism can be incorporated into a 
bread such that the food product has a maximum of 160 mg 
Steviol glycoside/kg food on a dry weight basis. A Steviol 
glycoside composition produced by a recombinant micro 
organism, plant, or plant cell can be incorporated into a hard 
or soft candy Such that the food product has a maximum of 
1600 mg Steviol glycoside/kg food on a dry weight basis. A 
Steviol glycoside composition produced by a recombinant 
microorganism, plant, or plant cell can be incorporated into 
a processed fruit product (e.g., fruit juices, fruit filling, jams, 
and jellies) Such that the food product has a maximum of 
1000 mg Steviol glycoside/kg food on a dry weight basis. 
0.165 For example, such a steviol glycoside composition 
can have from 90-99% RebA and an undetectable amount of 
Stevia plant-derived contaminants, and be incorporated into 
a food product at from 25-1600 mg/kg, e.g., 100-500 mg/kg, 
25-100 mg/kg, 250-1000 mg/kg, 50-500 mg/kg or 500-1000 
mg/kg on a dry weight basis. 
0166 Such a steviol glycoside composition can be a 
RebB-enriched composition having greater than 3% RebB 
and be incorporated into the food product such that the 
amount of RebB in the product is from 25-1600 mg/kg, e.g., 
100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 
mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, 
the RebB-enriched composition has an undetectable amount 
of Stevia plant-derived contaminants. 
0167 Such a steviol glycoside composition can be a 
RebD-enriched composition having greater than 3% RebD 
and be incorporated into the food product such that the 
amount of RebD in the product is from 25-1600 mg/kg, e.g., 
100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 
mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, 
the RebD-enriched composition has an undetectable amount 
of Stevia plant-derived contaminants. 
0168 Such a steviol glycoside composition can be a 
RebE-enriched composition having greater than 3% RebE 
and be incorporated into the food product such that the 
amount of RebE in the product is from 25-1600 mg/kg, e.g., 
100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 
mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, 
the RebE-enriched composition has an undetectable amount 
of Stevia plant-derived contaminants. 
0169. Such a steviol glycoside composition can be a 
RebM-enriched composition having greater than 3% RebM 
and be incorporated into the food product such that the 
amount of RebM in the product is from 25-1600 mg/kg, e.g., 
100-500 mg/kg, 25-100 mg/kg, 250-1000 mg/kg, 50-500 
mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, 
the RebM-enriched composition has an undetectable amount 
of Stevia plant-derived contaminants. 
0170 In some embodiments, a substantially pure steviol 
or Steviol glycoside is incorporated into a tabletop Sweetener 
or "cup-for-cup' product. Such products typically are 
diluted to the appropriate sweetness level with one or more 
bulking agents, e.g., maltodextrins, known to those skilled in 
the art. Steviol glycoside compositions enriched for RebA, 
RebB, RebD, RebE, or RebM, can be package in a sachet, 
for example, at from 10,000 to 30,000 mg steviol glycoside/ 
kg product on a dry weight basis, for tabletop use. 
(0171 The invention will be further described in the 
following examples, which do not limit the scope of the 
invention described in the claims. 
EXAMPLES 
0172. The Examples that follow are illustrative of spe 
cific embodiments of the invention, and various uses thereof. 
They are set forth for explanatory purposes only, and are not 
to be taken as limiting the invention. 
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Example 1. LC-MS Analytical Procedures 
(0173 The LC-MS methods described here are oriented 
towards the separation, general detection and potential iden 
tification of chemicals of particular masses (i.e. Steviol 
glycosides) in the presence of a mixture (i.e. culture media). 
LC-MS analyses were performed on: (A) an UltiMateR) 
3000-TSQ (Thermo Fisher Scientific); (B) a 1290 Infitity— 
6130SQ (Agilent); or (C) an Acquity—XevoTQD (Waters) 
system. Specific methods used for each system are described 
below. 
0.174 Method A: 
0.175 LC-MS analyses were performed using an Ulti 
Mate(R) 3000 UPLC system (Dionex) fitted with a waters 
ACQUITY UPLCR BEH shield RP18 column (2.1x50mm, 1.7 um particles, 130 A pore size) connected to a TSQ 
Quantum R. Access (ThermoFisher Scientific) triple quadro 
pole mass spectrometer with a heated electrospray ion 
(HESI) source, unless otherwise indicated. Elution was 
carried out using a mobile phase of eluent B (MeCN with 
0.1% Formic acid) and eluent A (water with 0.1% Formic 
acid) by increasing the gradient from 25% to 47% B from 
min. 0.0 to 4.0, increasing 47% to 100% B in min. 4.0 to 5.0, 
holding 100% B from min. 5.0 to 6.5 re-equilibration. The 
flow rate was 0.4 mL/min and the column temperature 35° 
C. The steviol glycosides were detected using SIM (Single 
Ion Monitoring) with the following m/Z-traces. 
TABLE 1. 
MS analytical information for Stevio Glycosides 
compound 
Description Exact Mass miz trace (typical t in min) 
Steviol + M + HI'' 481.2 + 0.5 19-SMG (2.29), 
1 Glucose 481.2796 503.1 + 0.5 13-SMG (3.5) 
M + Na)" 
SO3.2615 
Steviol + M + Na)" 665 + 0.5 Rubusoside (2.52) 
2 Glucose 665.3149 Steviol-1,2-bioside (2.92) 
Steviol-1,3-bioside (2.28) 
Steviol + M + Na)" 827.4 + 0.5 12-Stevioside (2.01) 
3 Glucose 827.3677 1,3-Stevioside (2.39) 
RebB (2.88) 
Steviol + M + Na)" 989.4 + 0.5 RebA (2.0) 
4 Glucose 989.42OO 
Steviol + M + Nat 1151.4 + 0.5 RebD (1.1) 
5 Glucose 1151.4728 
Steviol + M + Na' 1313.5 + 0.5 RebM (1.3) 
6 Glucose 1313.5257 
0176 The levels of steviol glycosides were quantified by 
comparing with calibration curves obtained with authentic 
standards from LGC Standards. For example, standard solu 
tions of 0.5 to 100 uM RebA were typically utilized to 
construct a calibration curve. 
(0177 Method B: 
0.178 A second analytical method was performed on the 
Agilent system 1290 Infinity fitted with a waters ACQUITY 
UPLCR BEH shield RP18 column (2.1x50 mm, 1.7 um 
particles, 130 A pore size, Waters) was connected to a 6130 
single quadrupol mass detector (Agilent) with a APCI ion 
Source. Elution was carried out using a mobile phase of 
eluent B (MeCN with 0.1% Formic acid) and eluent A (water 
with 0.1% Formic acid) by increasing the gradient from 23% 
to 47% B from min. 0.0 to 4.0, increasing 47% to 100% B 
in min. 4.0 to 5.0, holding 100% B from min. 5.0 to 6.5 
re-equilibration. The flow rate was 0.6 mL/min and the 
column temperature 50° C. The steviol glycosides were 
detected using SIM (Single Ion Monitoring) with the fol 
lowing m/Z-traces. 
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compound 
(typical t in min) 
RebM (0.91) 
Rubusoside 
1.2-Stevioside (1.44) 
1,3-stevioside (1.74) 
RebD (0.81) 
19SMG (2.49) 
13SMG (2.65) 
RebA (1.42) 
1.2-Stevioside (2.16) 
1,3-Stevioside (2.34) 
RebB (2.13) 
TABLE 2 
MS analytical information for Steviol Glycosides 
SIM time mz 
trace No window trace Exact Mass Description 
1 0.0-1.51 min 1289.5 M – H. Steviol + 
1289.5281 6 Glucose 
1.51-1.90 min 687.3 M + HCOOH - H. Steviol + 
687.3217 2 Glucose 
1.90-5.0 min 641.O M – H. Steviol + 
641.31 68 2 Glucose 
2 0.0-1.0 min 1127.4 M – H. Steviol + 
1127.4752 5 Glucose 
1.0-5.0 min 525.3 M - HCOOH - H Steviol + 
S25.2689 1 Glucose 
3 0.0-2.8 min 965.4 M – H. Steviol + 
965.4224 4 Glucose 
4 0.0–3.2 min 8O3.4 M – H. Steviol + 
8O3.3696 2 Glucose 
0179 The levels of steviol glycosides were quantified by 
comparing with calibration curves obtained with authentic 
standards from LGC Standards. For example, standard solu 
tions of 0.3 to 25 uM RebA were typically utilized to 
construct a calibration curve. 
0180 Method C: 
0181. A third analytical method used was LC-MS analy 
ses performed using a Waters ACQUITY UPLC (Waters 
Corporation, Milford, Mass.) with Waters ACQUITY 
UPLCR BEH C18 column (2.1x50 mm, 1.7 um particles, 
130 A pore size) coupled to a Waters ACQUITY TOD triple 
quadropole mass spectrometer with electrospray ionization 
(ESI) in negative mode. Compound separation was achieved 
by a gradient of the two mobile phases A (water with 0.1% 
formic acid) and B (MeCN with 0.1% formic acid) by 
increasing from 20% to 50% B between 0.3 to 2.0 min, 
increasing to 100% B at 2.01 min, holding 100% B for 0.6 
min and re-equilibrate for another 0.6 min. The flow rate was 
0.6 mL/min and the column temperature 55° C. RebD (m/z 
1127.5), RebM (m/z 1289.5), redaudioside A (m/z 965.4) 
and RebB (m/z, 803.4) were monitored using SIM (Single 
Ion Monitoring) and quantified by comparing with authentic 
standards. 
Example 2. Construction of a Steviol 
Glycoside-Producing Yeast Strain 
0182 Steviol glycoside-producing S. cerevisiae strains 
were constructed as described in WO 2011/153378, WO 
2013/022989, WO 2014/122227, and WO 2014/122328, 
each of which is incorporated by reference in its entirety. For 
example, a yeast Strain comprising a recombinant gene 
encoding a Synechococcus sp. GGPPS polypeptide (SEQID 
NO:1, SEQ ID NO:149), a recombinant gene encoding a 
truncated Zea mays CDPS polypeptide (SEQ ID NO:2, SEQ 
ID NO:150), a recombinant gene encoding an A. thaliana 
KS polypeptide (SEQID NO:3, SEQID NO:151), a recom 
binant gene encoding a recombinant S. rebaudiana KO1 
polypeptide (SEQ ID NO:4, SEQ ID NO:152), a recombi 
nant gene encoding an A. thaliana ATR2 polypeptide (SEQ 
ID NO:5, SEQ ID NO:153), a recombinant gene encoding 
an O. sativa EUGT11 polypeptide (SEQID NO:12: SEQ ID 
NO:148), a recombinant gene encoding an Srk AHe1 poly 
peptide (SEQ ID NO:6, SEQ ID NO:154), a recombinant 
gene encoding an S. rebaudiana CPR8 polypeptide (SEQID 
NO:7, SEQID NO:155), a recombinant gene encoding an S. 
rebaudiana UGT85C2 polypeptide (SEQID NO:8, SEQID 
NO:156), a recombinant gene encoding an S. rebaudiana 
UGT74G1 polypeptide (SEQ ID NO:9, SEQID NO:157), a 
recombinant gene encoding an S. rebaudiana UGT76G1 
polypeptide (SEQ ID NO:10, SEQ ID NO:158), and a 
recombinant gene encoding an S. rebaudiana UGT91D2 
variant (or functional homolog), UGT91D2e-b (SEQ ID 
NO:11, SEQ ID NO:159) polypeptide produced steviol 
glycosides. As analyzed by LC-MS (Method C) following 
DMSO-extraction of total steviol glycosides from the whole 
cell and broth mixture (total production), the strain produced 
between 18-21 lug/mL or 1-1.5 g/mL/ODoo RebM after 
growth for five days in 1 mL SC (Synthetic Complete) media 
at 30° C. with 400 rpm shaking in deep-well plates. See 
Table 3. 
TABLE 3 
Steviol glycoside production in a representative 
S. cerevisiae strain comprising genes encoding GGPPS, 
truncated CDPS, KS, KO, ATR2, EUGT11, SrKAHe1, CPR8, 
UGT85C2, UGT74G1, UGT76G1, and EUGT11 polypeptides. 
RebB RebA RebD RebM 
(ig/mL (g/mL/ (g/mL/ (gfmL Normalized by 
ODsoo) ODsoo) ODsoo) ODsoo) ODsoo 
O.21 O.33 O.33 1.3 Average 
O.O28 O.OS4 O.O32 O.14 Stod Deviation 
RebB RebA RebD RebM 
(g/mL) (Ig/mL) (Lig/mL) (Lig/mL) 
3.1 4.9 S.O 19.0 Average 
O42 O.81 O48 2.1 Stod Deviation 
0183. A second strain, which comprised additional copies 
of the genes of the first strain, was analyzed for Steviol 
glycoside production. The second strain produced RebD and 
RebM as primary Steviol glycosides, although at higher 
levels than the first strain. 
(0.184 As analyzed by LC-MS (Method C) following 
DMSO-extraction of total steviol glycosides from the whole 
cell and broth mixture (total production), the second strain 
produced between 60-80 ug/mL or 4-6 lug/mL/ODoo RebM. 
after growth for five days in 1 mL SC media at 30°C. with 
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400 rpm shaking in deep-well plates. Production of RebA, 
RebB, RebD and RebM by the second strain is shown in 
Table 4. 
TABLE 4 
Steviol glycoside production in an S. cerevisiae strain 
comprising additional copies of genes encoding GGPPS, 
truncated CDPS, KS, KO, ATR2, EUGT11, SrKAHe1, CPR8, 
UGT85C2, UGT74G1, UGT76G1, and EUGT11 polypeptides. 
RebA RebB RebD RebM 
(g/mL (Lig/mL/ (Lig/mL/ (gfmL Normalized by 
ODoo) ODoo) ODsoo) ODsoo) ODsoo 
2.1 0.67 1.6 4.8 Average 
O.66 O.21 0.75 2.3 Stod Deviation 
RebA RebB RebD RebM 
(g/mL) (Ig/mL) (ig/mL) (ig/mL) 
31.0 10.1 23.7 72.5 Average 
9.9 3.1 11.3 34.4 Stod Deviation 
Example 3. Knockout of Yeast Endogenous 
Transport Genes and Transport-Related Genes 
0185. Observations from deep-well studies of Example 2 
and similar strains indicated that the fraction of RebA, 
RebB, RebD or RebM in the supernatant changes with time, 
and the effect was determined not to be the result of cell 
lysis. To determine the effect of various transporters on 
Steviol glycoside excretion in S. cerevisiae, deletion cas 
settes for homologous recombination were obtained by 
designing primers annealing approximately 200 bp upstream 
and downstream of the open reading frame (ORF) and then 
amplifying the ORF-specific deletion cassette from the S. 
cerevisiae deletion collection. The candidate genes selected 
include identified ORFs with relation to transport or com 
prising membrane spanning domains, regardless of Subcel 
lular localization. In the resulting colonies, the presence of 
the deletion cassette at the correct locus was verified by 
colony PCR. A maximum of 6 clones of each deletion was 
frozen down as freezer Stock. All samples for analysis were 
initiated from the freezer stock and grown in SC medium for 
5 days (30° C., shaking 400 rpm) prior to harvest and 
extraction of samples for LC-MS. Samples were analyzed 
for the presence of RebA, RebB, RebD and RebM in the 
culture broth lacking cells (Supernatant) as well as in the 
whole cell and broth mixture (Total production). 
0186 Concentrations of total and supernatant RebA, 
RebB, RebD and RebM were compared to the levels in a 
control Steviol glycoside-producing strain. The amounts of 
RebA, RebB, RebD and RebM in each sample were nor 
malized to the control strain by dividing the value of a 
particular Steviol glycoside with the corresponding value for 
the control Strain, thereby calculating a percentage to the 
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control strain, where 1 equals 100 percent. The “ideal 
candidate' would exhibit a decrease in RebA, RebB, RebD 
and/or RebM levels in the supernatant, as compared to the 
control Steviol glycoside-producing strain, without decreas 
ing RebA, RebB, RebD, and/or RebM total production. 
0187. The effect of yeast gene knockouts on transport of 
higher molecular weight Steviol glycosides into the culture 
medium was tested in a strain that produces Steviol glyco 
sides, such as the strains described in Example 2. Disruption 
of each specific transporter gene was performed by homolo 
gous recombination. After 5 days of growth in 1 mL SC 
medium at 30° C. and 400 rpm, cells were harvested. A 50 
uL aliquot of the culture was mixed with an equal volume of 
100% DMSO, vortexed, and heated to 80° C. for 10 min. 
The suspension was then centrifuged to remove cell debris. 
60 uL of the mixture were analyzed by LC-MS as the “Total 
sample. The remaining culture was then centrifuged to pellet 
cells. An aliquot of 50 uL was removed from the supernatant 
(i.e., the culture medium) and mixed with an equal volume 
of 100% DMSO. The suspension was heated to 80° C. for 10 
min and centrifuged. 60 uL of the mixture were analysed by 
LC-MS as the “Supernatant sample. The amounts of higher 
molecular weight Steviol glycosides (including RebA, 
RebB, RebD, RebM) were measured by LC-MS (Method 
C), as described in Example 
0188 The data demonstrate that disruption of a single 
endogenous yeast transporter gene in a Steviol glycoside 
producing strain resulted in a decrease in the level of various 
Steviol glycosides in the Supernatant of the culture media, as 
evaluated by the normalized amount transported into the 
supernatant (see Tables 5-10). Tables 5-10 comprise lists of 
transport related genes that were knocked out in a steviol 
glycoside-producing strain. More specifically, Table 5 com 
prises a compiled list of genes by ordered locus name found 
to affect Steviol glycoside excretion in Steviol glycoside 
producing strains and are therefore identified as having a 
role in Steviol glycoside excretion. When the specified genes 
were knocked out, a more than 40% decrease in either the 
Supernatant alone or in the ratio of Supernatant/total produc 
tion of RebA, RebB, RebD, and/or RebM was observed. 
This corresponded approximately to more than 2 standard 
deviations removed from the mean of a control steviol 
glycoside-producing Strain (a value of 1 equals 100 percent 
of the control strain, whereas a value of 0.5 indicates a 50% 
decrease). 
0189 Table 6 comprises a compiled list of genes by 
ordered locus name found to affect Steviol glycoside excre 
tion in Steviol glycoside-producing strains and are therefore 
identified as having a role in Steviol glycoside excretion. 
When knocked out, these genes caused a mean of between 
20-40% decrease in either the supernatant alone or in the 
ratio of Supernatant/total production. This corresponded to 
approximately between 1 and 2 standard deviations removed 
from the mean of the control strain (a value of 1 equals 100 
percent of the control strain, whereas a value of 0.5 indicates 
a 50% decrease). 
TABLE 5 
Transport related genes with over a 40% decrease in Reb A, RebB, RebD or 
SEQ 
ID 
No. 
13 
14 
RebM levels compared to a control Steviol glycoside-producing strain. 
A. 
Ordered Uniprot 
Locus Gene Accession 
Name Family Description l8le No. 
YBR18OW MFS Secondary Transporter DTR1 P381.25 
YALO67C MFS Secondary Transporter SEO1 P39709 
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TABLE 5-continued 
Transport related genes with over a 40% decrease in Reb A, RebB, RebD or 
RebM levels compared to a control Steviol glycoside-producing strain. 
15 YBLO89W AAAP Secondary Transporter AVT5 P38176 
16 YBLO99W F-ATPase ATP-Dependent ATP1 PO7251 
17 YBR241C MFS Secondary Transporter P38142 
18 YBR294W SIP Secondary Transporter SUL1 P38359 
19 YCLO69W MFS Secondary Transporter VBA3 P25594 
20 YCRO28C MFS Secondary Transporter FEN2 P25621 
21 YCRO75C LCT Secondary Transporter ERS1 P17261 
22 YDL128W CaCA Secondary Transporter VCX1 Q99385 
23 YDL18SW F-ATPase ATP-Dependen WMA1 P17255 
24 YDL194W MFS Secondary Transporter SNF3 P10870 
25 YDL21OW APC Secondary Transporter UGA4 P32837 
26 YDRO61W ABC ATP-Dependen Q12298 
27 YDRO93W P-ATPase ATP-Dependen DNF2 Q12675 
28 YDR338C MOPMATE Secondary Transporter Q05497 
29 YDR406W ABC ATP-Dependen PDR15 Q04182 
30 YDR536W MFS Secondary Transporter STL1 P39932 
31 YELO31W P-ATPas ATP-Dependen SPF1 P39986 
32 YER166W P-ATPase ATP-Dependen DNF1 P32660 
33 YFLO11W MFS Secondary Transporter HXT10 P43581 
34 YGLOO6W P-ATPase ATP-Dependen PMC1 P38929 
35 YGLO13C Transcription factor PDR1 P12383 
36 YGL255W ZIP Secondary Transporter ZRT1 P32804 
37 YGR125W SuP Secondary Transporter P53273 
38 YGR181W MPT ATP-Dependen TIM13 P53299 
39 YGR217W VIC Ion Channels CCH1 P5007 7 
40 YGR224W MFS Secondary Transporter AZR1 P5008O 
41 YGR281W ABC ATP-Dependen YOR1 P53049 
42 YHLO16C SSS Secondary Transporter DUR3 P334.13 
43 YILO88C AAAP Secondary Transporter AVT7 P4OSO1 
44 YULO93C VIC Ion Channels TOK1 P4O310 
4S YULO94C CPA2 Secondary Transporter KHA1 P40309 
46 YTL108C Thire Secondary Transporter PRM10 P42946 
47 YTL212C OPT Secondary Transporter OPT1 P40897 
48 YJR106W. CaCA Secondary Transporter ECM27 P47144 
B. 
Ordered Uniprot 
Locus Gene Accession 
No. Name Family Description l8le No. 
49 YR16OC MFS Secondary Transporter MPH3 POCEOO 
SO YKLO64W MIT Ion Channels MNR2 P35724 
51 YKROSOW Trk Secondary Transporter TRK2 P28584 
52 YKR105C MFS Secondary Transporter VBA5 P36172 
53 YKR106W MFS Secondary Transporter GEX2 P36173 
S4 YLR447C F-ATPase ATP-Dependent VMA6 P32366 
55 YML116W MFS Secondary Transporter SNQ1/ATR1 P13090 
S6 YMRO34C BASS Secondary Transporter Q05131 
57 YMRO56C MC Secondary Transporter AAC1 PO4710 
58 YMR253C DMT Secondary Transporter Q04835 
59 YNLO65W MFS Secondary Transporter AQR1 P53943 
60 YNLO7OW MPT ATP-Dependent TOM7 P53507 
61 YNLO83W MC Secondary Transporter SAL1 D6W196 
62 YNLO95C AEC Secondary Transporter P53932 
63 YNL121C MPT ATP-Dependent TOM 70 PO7213 
64 YNL142W Amt Ion Channels MEP2 P41948 
65 YOLO2OW APC Secondary Transporter TAT2 P38967 
66 YOLO75C ABC ATP-Dependent Q08234 
67 YOLO77W-A F-ATPase ATP-Dependent ATP19 P814S1 
68 YOL122C Nramp Secondary Transporter SMF1 P389.25 
69 YORO79C ZIP Secondary Transporter ATX2 Q12067 
70 YORO87W TRP-CC Ion Channels YVC1 Q12324 
71 YORO92W AEC Secondary Transporter ECM3 Q99252 
72 YOR130C MC Secondary Transporter ORT1 Q12375 
73 YOR222W MC Secondary Transporter ODC2 Q99297 
74 YOR291W P-ATPase ATP-Dependent YPK9 Q12697 
75 YOR306C MFS Secondary Transporter MCH5 Q08777 
76 YOR316C CDF Secondary Transporter COT1 P32798 
77 YOR334W MIT Ion Channels MRS2 Q01926 
78 YPLO78C F-ATPase ATP-Dependent ATP4 PO5626 
79 YPL27OW ABC ATP-Dependent MDL2 P33311 
80 YPL274W APC Secondary Transporter SAM3 Q08986 
81 YPROO3C SIP Secondary Transporter P53394 
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Transport related genes with over a 40% decrease in Reb A, RebB, RebD or 
RebM levels compared to a control Steviol glycoside-producing strain. 
82 
83 
84 
85 
SEQ 
ID 
No. 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
96 
97 
98 
99 
OO 
O1 
O2 
O3 
O4 
05 
O6 
O7 
O8 
09 
10 
11 
12 
13 
14 
15 
No. 
16 
17 
18 
19 
2O 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
YPRO11C 
YPRO58W 
YPR128C 
YPR201W 
MC 
MC 
MC 
ACR3 
Secondary Transporter 
Secondary Transporter YMC1 
Secondary Transporter ANT1 
Secondary Transporter ARR3 
TABLE 6 
Q12251 
P32331 
Q06497 
Q06598 
Transport related genes with a 20-40% decrease in Reb A, RebB, RebD or 
RebM levels compared to a control Steviol glycoside-producing strain. 
Ordered 
Locus 
Name 
Ordered 
Locus 
Name 
M S 
ABC 
GUP 
MFS 
OPT 
P-ATPase 
MC 
ABC 
APC 
Family 
MC 
MFS 
MC 
MFS 
MFS 
MFS 
MC 
MFS 
F-ATPase 
MIT 
MC 
AAAP 
ABC 
APC 
Ctr 
DMT 
MC 
MFS 
A. 
Description 
Secon Trans 
Secondary Trans 
Secon 8S 
8S 
el 
Trans 
Trans 
el 
8S 
el 
Trans 
Trans 
el 
el 
Trans 
Trans 
el 
8S 
el 
Trans 
Trans 
el 
8S 
8S 
8S 
8S 
indent 
Trans 
indent 
Trans 
airy 
AA PP DeDe 
S 
. De E. l 
S e C O l 
A. P De i S 
. De E. n 
N 
A. C D e e n 
Al P De s 
S. 
S e C O l airy 
Description 
Secon 8S 
Secondary Trans 
Secon Trans 
Secon 
Secon 
airy 
: 
s 
al 
8S 
Trans 
Secon Trans 
Secon Trans 
Secon Trans 
ATP-Dependent 
Ion Channels 
Secon Trans 
Secondary Trans 
ATP-Dependent 
Secondary Trans 
Ion Channels 
Secondary Trans 
Secondary Trans 
Secondary Trans 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
borter 
Gene 
l8le 
FLR1 
FUR4 
QDR3 
PCA1 
PHO89 
ATG22 
ADP1 
MCH1 
GET3 
HXT15 
SRP101 
Gene 
l8le 
LEUS 
HXTS 
YIA6 
QDR1 
QDR2 
SOA1 
MRS3 
HXT9 
ATP7 
OAC1 
AVT3 
STE6 
GAP1 
CTR3 
YMD8 
Uniprot 
Accession 
No. 
P38124 
PO5316 
P38227 
P38355 
P3836O 
P38361 
P25568 
P253.71 
Q07376 
Q12154 
P54854 
POCD99 
P32568 
P32916 
P30605 
P39.953 
P25515 
P39980 
P52871 
P40035 
P4OO74 
P43569 
P43617 
P53154 
P53142 
P53134 
P13586 
P5332O 
P38735 
P38734 
Accession 
No. 
P38702 
P38695 
P40556 
P4O475 
P4O474 
P4O445 
P10566 
P40885 
P30902 
P35736 
P32332 
P36062 
P12866 
P19145 
Q06686 
Q03697 
Q03829 
Q03263 
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Transport related genes with a 20-40% decrease in Reb A, RebB, RebD or 
RebM levels compared to a control Steviol glycoside-producing strain. 
134 YNLOO3C MC Secondary Transporter PET8 
135 YNL268W APC Secondary Transporter LYP1 
136 YNRO55C MFS Secondary Transporter HOL1 
137 YOL158C MFS Secondary Transporter ENB1 
138 YOR1OOC MC Secondary Transporter CRC1 
139 YOR153W ABC ATP-Dependent PDR5 
140 YOR271C MTC Secondary Transporter FSF1 
141 YOR273C MFS Secondary Transporter TPO4 
142 YOR307C DMT Secondary Transporter SLY41 
143 YOR332W F-ATPase ATP-Dependent VMA4 
144 YOR348C APC Secondary Transporter PUT4 
145 YPLO36W P-ATPase ATP-Dependent PMA2 
0190. Steviol glycoside exporter candidates were 
selected from the data based on two selection criteria for 
each Steviol glycoside measured (L. e., two methods of 
normalizing expression). 
0191 Transporter selection criterion 1 corresponded to 
selection based on the level of high molecular weight Steviol 
glycosides (RebA, RebB, RebD, or RebM) available in the 
Supernatant, as well as the total production of the said Steviol 
glycoside. Both values were normalized to the value of the 
corresponding Steviol glycoside-producing control strain. 
The control level was set to 1, and the corresponding steviol 
glycoside level was calculated as a percentage of the control. 
For Ordered Locus Names (i.e., genes) of interest, the 
Steviol glycoside available in the supernatant should be 
below 0.6 (below 60% of the control) or between 0.8-0.6 
(80-60% of the control). To avoid false positives or a bias 
towards transporters that decrease the production in general, 
the calculation had an additional requirement that the total 
production had to be similar to the control. In the current 
calculation, production was set to be between 0.85 and 1.15 
of the control, when the control is set to 1. In this regard, 
Steviol glycoside production levels did not affect results. 
Table 7 shows the supernatant/total ratio for each candidate 
that fulfills the selection criteria. 
0.192 Transporter selection criterion 2 corresponded to 
selection based on the ratio of high molecular weight Steviol 
glycosides (RebA, RebB, RebD, or RebM) in the superna 
tant relative to total production of the said steviol glycoside. 
The Supernatant-to-total production ratio was normalized to 
the ratio of the corresponding Steviol glycoside-producing 
strain control. The control level was set to 1, and the 
corresponding Steviol glycoside ratio was calculated as a 
percentage of the control. For Ordered Locus Names (i.e., 
genes) of interest, the Supernatant-to-total production ratio 
for a given steviol glycoside should be below 0.6 (below 
60% of the control) or between 0.8-0.6 (80-60% of the 
control). To avoid false positives or a bias towards trans 
porters that decrease the production in general, the calcula 
tion had an additional requirement that the total production 
had to be similar to the control. In the current calculation, 
production was set to be between 0.85 and 1.15 of the 
control, when the control is set to 1. In this regard, Steviol 
glycoside production levels did not affect results. Table 8 
shows the Supernatant/total ratio for each candidate that 
fulfills the selection criteria. 
0193 The data demonstrate that disruption of a single 
endogenous yeast transporter gene in a Steviol glycoside 
producing strain resulted in a decrease in the level of various 
P38921 
P32487 
P53389 
Q08299 
Q12289 
P333O2 
Q12029 
Q12256 
P22215 
P22203 
P1538O 
P19657 
Steviol glycosides in the Supernatant of the culture media, as 
evaluated by the normalized amount transported into the 
supernatant (see Tables 5-10), and are therefore identified as 
having a role in Steviol glycoside excretion. 
0194 For example, deletion in a steviol glycoside-pro 
ducing strain of YDL128W (SEQ ID NO:22), YDL194W 
(SEQ ID NO:24), YDL210W (SEQ ID NO:25), YFLO11W 
(SEQ ID NO:33), YGL006W (SEQ ID NO:34), YGL013C 
(SEQ ID NO:35), YGL255W (SEQ ID NO:36), YGR181W 
(SEQ ID NO:38), YGR217W (SEQ ID NO:39), YIL088C 
(SEQ ID NO:43), YJL094C (SEQ ID NO:45), YJR106W. 
(SEQ ID NO:48), YNL065W (SEQ ID NO:59), YNL083W 
(SEQ ID NO:61), YNL121C (SEQID NO:63), YNL142W 
(SEQID NO:64), YOR306C (SEQID NO:75), or YPR011C 
(SEQ ID NO:82) led to a measurable decrease of RebD 
excreted into the culture medium, indicating that each plays 
a role in RebD excretion. This was confirmed by transporter 
selection criteria 1 and 2 (see Tables 7 and 8, RebD column). 
0.195. Furthermore, for example, deletion in a steviol 
glycoside-producing strain of YBR180W (SEQID NO:13), 
YBR241C (SEQ ID NO:17), YCL069W (SEQ ID NO:19), 
YCR075C (SEQ ID NO:21), YDL128W (SEQ ID NO:22), 
YDL194W (SEQ ID NO:24), YDRO93W (SEQ ID NO:27), 
YDR338C (SEQ ID NO:28), YER166W (SEQ ID NO:32), 
YFLO11W (SEQ ID NO:33), YGL006W (SEQ ID NO:34), 
YGL013C (SEQ ID NO:35), YGL255W (SEQ ID NO:36), 
YGR217W (SEQ ID NO:39), YJL094C (SEQ ID NO:45), 
YJR106W (SEQ ID NO:48), YJR160C (SEQ ID NO:49), 
YKR106W (SEQ ID NO:53), YML116W (SEQ ID NO:55), 
YMR056C (SEQID NO:57), YNL070W (SEQ ID NO:60), 
YNL083W (SEQ ID NO:61), YNL095C (SEQ ID NO:62), 
YNL121C (SEQ ID NO:63), YOR087W (SEQ ID NO:70), 
YOR291W (SEQ ID NO:74), YOR306C (SEQ ID NO:75), 
YPL274W (SEQID NO:80), or YPR011C (SEQID NO:82) 
led to a measurable decrease of RebM, indicating that each 
plays a role in RebM excretion. This was confirmed by 
transporter selection criteria 1 and 2 (see Tables 7 and 8. 
RebM column). 
0196) Table 7 represents the calculated ratio, normalized 
to a Steviol glycoside-producing strain comprising genes 
encoding GGPPS, truncated CDPS, KS, KO, ATR2, 
EUGT11, SrKAHe1, CPR8, UGT85C2, UGT74G1, 
UGT76G1, and EUGT11 polypeptides, of supernatant/total 
production for each gene (by ordered locus name) deleted in 
the Steviol glycoside-producing strain. The Supernatant or 
supernatant/total ratio of less than 0.6 represented a more 
than 40% decrease in either the supernatant alone or in the 
ratio of supernatant/total production of RebA, RebB, RebD, 
US 2017/021841 8 A1 
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or RebM, which corresponded approximately to more than 
2 standard deviations removed from the mean of the control 
Steviol glycoside-producing strain and indicates the gene as 
having a role in Steviol glycoside transportation (Table 7). 
The supernatant or ratio supernatant/total of between 0.6 and 
0.8 represents a 40-20% decrease in either the supernatant 
alone or in the ratio of supernatant/total production of RebA, 
RebB, RebD, or RebM, which corresponds to approximately 
Aug. 3, 2017 
between 1 and 2 standard deviations removed from the mean 
of the control Steviol glycoside-producing Strain, and indi 
cates the gene as having a role in Steviol glycoside trans 
portation and/or production (Table 8). Total production of 
each steviol glycoside was between 0.85 and 1.15 compared 
to the Steviol glycoside-producing strain. Table 8 shows the 
supernatant/total ratio for each candidate that fulfills the 
selection criteria. 
TABLE 7 
Transport related genes with over a 40% decrease in RebA, RebB, RebD 
or RebM compared to a control Steviol glycoside-producing strain comprising 
genes encoding GGPPS, truncated CDPS, KS, KO, ATR2, EUGT11, SrKAHe1, 
CPR8, UGT85C2, UGT74G1, UGT76Gl, and EUGT11 polypeptides. 
Transporter selection 
criterion 1 
Total VS. Supernatant 
Transporter selection 
criterion 2 
Ratio Sup/Total VS. Total 
Transport related genes with a 20-40% decrease in Reb A, RebB, RebD 
or RebM compared to a control Steviol glycoside-producing strain comprising 
genes encoding GGPPS, truncated CDPS, KS, KO, ATR2, EUGT11, SrKAHe1, 
CPR8, UGT85C2, UGT74G1, UGT76Gl, and EUGT11 polypeptides. 
YBROO8C 
Transports call: total VS Sup Transports call 2: ratio Sup/total vs total 
RebA RebB RebD RebM RebA RebB RebD RebM 
0.739 0.739 
O.784 O640 O.784 O640 
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TABLE 8-continued 
Transport related genes with a 20-40% decrease in Reb A, RebB, RebD 
or RebM compared to a control Steviol glycoside-producing strain comprising 
genes encoding GGPPS, truncated CDPS, KS, KO, ATR2, EUGT11, SrKAHe1, 
CPR8, UGT85C2, UGT74G1, UGT76Gl, and EUGT11 polypeptides. 
Transports call total VS Sup - Transports Cal 2: ratio Sup/total VS total 
RebA RebB RebD RebM RebA RebB RebD 
YOR273C O.726 O.916 0.635 O.726 O.63S 
YOR291W 
YOR307C 
YOR348C O644 
YPLO36W O.763 O.698 O.763 O.698 
YPLO78C O.798 O.798 
YPL27OW O.746 O.665 0.746 
YPL274W O.817 O.807 0.721 O.721 
YPRO11C O.763 O.763 
0197) The effect of yeast gene knockouts on transport of 
higher molecular weight Steviol glycosides into the culture 
medium (i.e., Supernatant) also was tested in a Steviol 
glycoside-producing strain comprising additional copies of 
genes encoding GGPPS, truncated CDPS, KS, KO, ATR2, 
EUGT11, SrKAHe1, CPR8, UGT85C2, UGT74G1, 
UGT76G1, and EUGT11 polypeptides, which was described 
in Example 2. The data demonstrated that disruption of a 
single endogenous yeast transporter gene in the Steviol 
glycoside-producing strain resulted in a decrease in the level 
of various steviol glycosides in the supernatant of the culture 
media, as evaluated by the normalized amount transported 
or by the supernatant-to-total-production ratio (see Tables 9 
and 10, RebD column). For example, deletion in the steviol 
glycoside-producing strain of YDR536W (SEQ ID NO:30), 
YHL016C (SEQ ID NO:42), YKRO50W (SEQ ID NO:51), 
YOR291W (SEQID NO:74), YOR334W (SEQ ID NO:77), 
YPL270W (SEQ ID NO:79), YPR058W (SEQ ID NO:83), 
or YPR128C (SEQ ID NO:84) led to a measurable decrease 
of RebD transported into the Supernatant, indicating that 
they play a role in RebD excretion. This was confirmed by 
transporter selection criteria 1 and 2 (see Tables 9 and 10, 
RebD column). 
(0198 Furthermore, for example, deletion of YAL067C 
(SEQ ID NO:14), YDR406W (SEQ ID NO:29), YHL016C 
(SEQ ID NO:42), YJL212C (SEQ ID NO:47), YKR050W 
(SEQ ID NO:51), YMR034C (SEQ ID NO:56), YMR253C 
(SEQ ID NO:58), YOLO75C (SEQ ID NO:66), YOL122C 
(SEQ ID NO:68), YOR222W (SEQ ID NO:73), YPR003C 
(SEQ ID NO:81), or YPR201W (SEQ ID NO:85) led to a 
measurable decrease of RebM transported into the superna 
RebM 
O681 
0.765 
O644 
O611 
tant, indicating that they play a role in RebM excretion. This 
was confirmed by transporter selection criteria 1 and 2 (see 
Tables 9 and 10, RebM column). 
0199 Table 9 represents the calculated ratio, normalized 
to a Steviol glycoside-producing strain comprising addi 
tional copies of genes encoding GGPPS, truncated CDPS, 
KS, KO, ATR2, EUGT11, SrKAHe1, CPR8, UGT85C2, 
UGT74G1, UGT76G1, and EUGT11 polypeptides, of super 
natant/total production for each gene (by ordered locus 
name) deleted in the Steviol glycoside-producing strain. The 
supernatant or ratio Supernatant/total of less than 0.6 repre 
sents a more than 40% decrease in either the supernatant 
alone or in the ratio of supernatant/total production of RebA, 
RebB, RebD, or RebM, which corresponds approximately to 
more than 2 standard deviations removed from the mean of 
a control Steviol glycoside-producing strain, and indicates 
the gene as having a role in Steviol glycoside transportation 
and/or production (Table 9). The supernatant or ratio super 
natant/total of between 0.6 and 0.8 represents a 40-20% 
decrease in either the Supernatant alone or in the ratio of 
supernatant/total production of RebA, RebB, RebD, or 
RebM, which corresponds to approximately between 1 and 
2 standard deviations removed from the mean of the control 
strain, and indicates the gene as having a role in Steviol 
glycoside transportation and/or production, and indicates the 
gene as having a role in Steviol glycoside transportation 
and/or production (Table 10). Total production of each 
Steviol glycoside was between 0.85 and 1.15 compared to 
the control steviol glycoside-producing strain. Table 10 
shows the Supernatant/total ratio for each candidate that 
fulfills the selection criteria. 
TABLE 9 
Transport related genes with over a 40% decrease in Reb A, 
RebB, RebD or RebM compared to a control steviol glycoside 
producing strain comprising additional copies of genes encoding 
GGPPS, truncated CDPS, KS, KO, ATR2, EUGT11, SrKAHe1, CPR8, 
UGT85C2, UGT74G1, UGT76Gl, and EUGT11 polypeptides. 
Transporter selection Transporter selection 
criterion 1 criterion 2 
total vs Sup ratio Sup/total vs total 
RebA RebB RebD RebM RebA RebB RebD RebM 
O541 O541 
O.433 0.416 O433 0.416 
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TABLE 10-continued 
Transport related genes with a 20-40% decrease in Reb A, RebB, 
RebD or RebM compared to a control steviol glycoside-producing 
strain comprising additional copies of genes encoding GGPPS, 
Aug. 3, 2017 
truncated CDPS, KS, KO, ATR2, EUGT11, SrKAHe1, CPR8, UGT85C2, 
UGT74G1, UGT76Gl, and EUGT11 polypeptides. 
Transports call: total VS Sup - Transport call 2: ratio Sup/total vs total 
RebA RebB RebD RebM RebA RebB RebD 
YMR166C O924 
YNLOO3C O.814 
YOR153W O.801 
YOR316C O.640 
YOR332W O.7OO O.7OO 
0200 Knockouts of YDL210W (SEQ ID NO:25) and 
YPL270W (SEQ ID NO:79) resulted in decreased RebD 
excretion in the Steviol glycoside-producing strain compris 
ing genes encoding GGPPS, truncated CDPS, KS, KO. 
ATR2, EUGT11, SrKAHe1, CPR8, UGT85C2, UGT74G1, 
UGT76G1, and EUGT11 polypeptides and the steviol gly 
coside-producing strain comprising additional copies of 
genes encoding GGPPS, truncated CDPS, KS, KO, ATR2, 
EUGT11, SrKAHe1, CPR8, UGT85C2, UGT74G1, 
UGT76G1, and EUGT11 polypeptides. As well, knockouts 
of YJL212C (SEQ ID NO:47) and YOL122C (SEQ ID 
NO:68) resulted in decreased RebM transport in both 
strains. 
Example 4. Confirmation of Knockout of Yeast 
Endogenous Transport Genes by Overexpression in 
a RebD/M-Producing Strain 
0201 Overexpression of a subset of the initial candidate 
transporters from Example 3 was performed using both 
plasmid-based expression and an integration cassette. First, 
deep-well microtiter plate culture experiments were carried 
out. Two transport genes were overexpressed using a plas 
mid in a RebD/M-producing strain in order to confirm the 
results from the knockout experiments. YGR181W (SEQ ID 
NO:38), a TIM complex, helper protein for insertion of 
mitochondrial inner membrane proteins, and YDR061W 
(SEQ ID NO:26) an ABC-like transporter were overex 
pressed. The data shown in FIG. 2 demonstrate that the 
phenotype based on the knockout studies was confirmed 
with a plasmid based overexpression phenotype for 
YGR181W (SEQ ID NO:38) and YDRO61W (SEQ ID 
NO:26) in deep-well plates. 
0202 Next, confirmation of the phenotype in fermenters 
was performed in additional Steviol glycoside-producing 
strains, which were characterized by intergration of 
YGR181W (SEQ ID NO:38) or YDR061W (SEQ ID 
NO:26) on chromosome XII. The steviol glycoside-produc 
ing strains were grown on defined media at 30° C. in a 
fed-batch fermentation for about 5 days under glucose 
limited conditions, and the levels of RebA, RebB, RebD, 
and RebM were measured using LC-MS (Method B, 
Example 1). The graphs shown in FIG. 3 illustrate an 
approximate 2-fold increase in RebD and RebM transported 
in the culture medium for the new integration constructs, and 
little change in RebA and RebB transport. Overexpression of 
YGR181W (SEQ ID NO:38) or YDR061W (SEQ ID 
NO:26) resulted in improved (-2-fold) RebD and RebM 
transport into the culture medium (~400-500 mg/L of super 
natant RebD and RebM in YGR181W (SEQ ID NO:38) and 
YDR061W (SEQ ID NO:26) overexpression strains versus 
~250 mg/L of supernatant RebD and RebM in a control 
RebM 
Steviol glycoside-producing strain). See FIG. 3A. The ratio 
of transported RebD as compared to the total RebD 
increased from 0.158 in the control strain to 0.21-0.25 with 
the candidate genes overexpressed. RebM transport into the 
culture medium was also simultaneously improved. See 
FIG. 3. 
Example 5. Overexpression of Selected Yeast 
Endogenous Transport Genes 
0203 Overexpression in a steviol glycoside-producing 
strain (as described in Example 2) using a plasmid with a 
constitutive promoter of the transporter genes shown in 
Table 11 resulted in greater than a 20% increase in excretion 
of RebA, RebB, RebD, and/or RebM. Results were analyzed 
using criterion 2 described in Example 3. Additionally, 
overexpression of the transporter genes shown in Table 12 
resulted in greater than a 40% improvement in production of 
RebA, RebB, RebD, and/or RebM. Table 11 shows the 
supernatant/total ratio for each candidate that fulfills the 
selection criteria. 
TABLE 11 
Transport related genes with over a 20% increase 
in RebA, RebB, RebD or RebM excretion, compared 
to a control steviol glycoside-producing strain. 
Ratio Supernatant Total 
RebB RebA RebD RebM 
YORO79C .21 
YMR166C 36 53 1.38 
YELO27W 62 82 1.52 
YDLO54C 45 38 1.31 
YKL12OW .83 89 1.93 
YDR536W .79 8O 1.76 
YBLO99W 122 
YML116W 32 31 1.42 
YIL166C 27 122 
YKRO39W 26 1.41 
YOR307C 1.23 
YKL146W 36 47 1.66 
YGL167C 1.33 
YJLO93C 1.29 
YOR306C 1.67 
YDL128W 1.85 29 
YOR153W 1.42 .21 
YKLOSOC 1.59 122 
YULO94C 1.71 1.24 .24 
YCLO69W 1.59 
YOL158C 1.52 
YFLO11W 1.44 
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TABLE 11-continued 
Transport related genes with over a 20% increase 
in RebA, RebB, RebD or RebM excretion, compared 
to a control steviol glycoside-producing strain. 
Ratio Supernatant Total 
RebB RebA RebD RebM 
YJR106W 1.38 1.33 
YBRO43C 1.2O 
YPRO11C 1.27 
TABLE 12 
Transport related genes with over a 40% increase 
in RebA, RebB, RebD or RebM production, compared 
to a control steviol glycoside-producing strain. 
Increases in Production 
RebB RebA RebD RebM 
YMR166C 52 
YIL166C 1.41 SO 55 
YKRO39W 48 52 
YKL146W 42 
YJLO93C 46 43 
YOR306C 59 
YDL128W 49 
YOL122C 41 59 
YILOO6W .64 2.03 
YFLO28C 55 
YBRO21W S1 87 
YHR002W S1 73 
YELO31W 45 66 
YCLO69W 53 
YOL158C 42 63 
YKLO64W 40 .44 
YHRO96C 42 
YOR332W .44 
YDR338C SO 55 
YJR106W 41 .44 
YBRO43C 55 49 
YPRO11C 43 
YFRO45W .44 
Example 6. Genomic Integration of Transporter 
Genes 
0204 DNA of the transporter genes selected for integra 
tion into the genome of a RebD/M-producing S. cerevisiae 
strain (see Example 2) was amplified from an S288C back 
ground by PCR and cloned into a plasmid with homology 
regions for the integration site and a PGK1 promoter for 
overexpression, using the USER cloning system. See, e.g., 
Nour-Eldin et al., 2010, Methods Mol Biol. 643:185-200. 
The USER cloning construct including the homology 
regions and the transporter was cut out from the plasmid 
using restriction enzymes, and the linear piece of DNA was 
integrated into the genome of the receiving RebD/M-pro 
ducing strain by standard LiAc method. The genomically 
integrated transporters were tested in plates that release 
glucose from a polymer after addition of a growth medium. 
A polymer that releases 20 g/L glucose over 3 days was used 
to mimic the feed profile during fermentation. Steviol gly 
coside levels were measured by LC-MS (see Example 1), 
and ODoo was measured on a PerkinElmer 2104 Multilabel 
reader. YBR043C (SEQ ID NO:88), YEL027W (SEQ ID 
NO:102), YJL093C (SEQ ID NO:44), YJR106W (SEQ ID 
NO:48), YKL120W (SEQ ID NO:126), and YMR166C 
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(SEQ ID NO:132) showed improved excretion of 13-SMG. 
(FIG. 4A). YBR043C (SEQID NO:88), YEL027W (SEQID 
NO:102), and YMR166C (SEQ ID NO:132) showed 
improved excretion of RebA (FIG. 4B). YBR043C (SEQ ID 
NO:88), YEL027W (SEQ ID NO:102), and YMR166C (SEQ ID NO:132) showed improved excretion of RebB 
(FIG. 4C). YBR043C of SEQID NO:88, YEL027W of SEQ 
ID NO:102, YJL093C of SEQID NO:44, YJR106W of SEQ 
ID NO:48, and YMR166C of SEQ ID NO: 132 showed 
improved production of RebD, and YBR043C of SEQ ID 
NO:88, YEL027W of SEQID NO:102, YIL166C (SEQ ID 
NO:121), YJL093C of SEQ ID NO:44, YJR106W of SEQ 
ID NO:48, and YMR166C of SEQ ID NO: 132 showed 
improved production of RebM, as measured by an increase 
in RebD and RebM levels in the supernatant compared to a 
control steviol glycoside-producing strain. See FIGS. 4D 
and 4E. Controls with a URA marker are also shown in FIG. 
4. 
(0205 FIG. 5A shows supernatant levels of RebA, RebB, 
RebD, and RebM of an additional steviol glycoside-produc 
ing strain overexpressing YMR166C (SEQ ID NO:132), 
YEL027W (SEQ ID NO:102), YKL120W (SEQ ID 
NO:126), YJR106W (SEQ ID NO:48), YJL093C (SEQ ID 
NO:44), and YBR043C (SEQ ID NO:88) by the USER 
cloning system. The strain of FIG. 5 comprised a recombi 
nant gene encoding a Synechococcus sp. GGPPS polypep 
tide (SEQ ID NO:1, SEQ ID NO:149), a recombinant gene 
encoding a truncated Zea mays CDPS polypeptide (SEQ ID 
NO:2, SEQID NO:150), a recombinant gene encoding an A. 
thaliana KS polypeptide (SEQ ID NO:3, SEQID NO:151), 
a recombinant gene encoding a recombinant S. rebaudiana 
KO1 polypeptide (SEQ ID NO:4, SEQ ID NO:152), a 
recombinant gene encoding a KO polypeptide (SEQ ID 
NO:XX, SEQID NO:XX), a recombinant gene encoding an 
A. thaliana ATR2 polypeptide (SEQ ID NO:5, SEQ ID 
NO:153), a recombinant gene encoding an O. sativa 
EUGT11 polypeptide (SEQID NO:12: SEQID NO:148), a 
recombinant gene encoding an SrKAHe1 polypeptide (SEQ 
ID NO:6, SEQ ID NO:154), a recombinant gene encoding 
an S. rebaudiana CPR8 polypeptide (SEQID NO:7, SEQID 
NO:155), a recombinant gene encoding an S. rebaudiana 
UGT85C2 polypeptide (SEQID NO:8, SEQID NO:156), a 
recombinant gene encoding an S. rebaudiana UGT74G1 
polypeptide (SEQ ID NO:9, SEQ ID NO:157), a recombi 
nant gene encoding an S. rebaudiana UGT76G1 polypeptide 
(SEQ ID NO:10, SEQID NO:158), and a recombinant gene 
encoding an S. rebaudiana UGT91D2 variant (or functional 
homolog), UGT91D2e-b (SEQID NO:11, SEQID NO:159) 
polypeptide. FIG. 5B shows total levels of RebA, RebB, 
RebD, and RebM of the above described steviol glycoside 
producing strain overexpressing YMR166C (SEQ ID 
NO:132), YEL027W (SEQ ID NO:102), YKL120W (SEQ 
ID NO.126), YIL166C (SEQ ID NO:132), YJR106W (SEQ 
ID NO:48), YJL093C (SEQ ID NO:44), and YBR043C (SEQ ID NO:88) by the USER cloning system. 
Example 7. Production of RebD and RebM by 
Fermentation of Steviol Glycoside-Producing S. 
cerevisiae Strains Overexpressing YJL093C or 
YBRO43C 
0206 YJL093C (SEQ ID NO:44) and YBR043C (SEQ 
ID NO:88) were individually overexpressed in the steviol 
glycoside-producing strain described in Example 3. The 
strains were cultivated by fermentation (fed-batch, mini 
mum medium, glucose-limiting) for approximately 130 h. 
Production of RebD and RebM was measured by LC-MS. 
As shown in Table 13, the strains overexpressing YJL093C 
or YBR043C produced higher levels of RebD and RebD+ 
RebM, as compared to a control Steviol glycoside-producing 
strain. 






































US 2017/021841 8 A1 
SEO ID NO: 
MATLLEHFOA 
OLKEKKPYOT 
KILTADKCMW 
SPREAWNFRR 
EWDWRDFFPY 
EGKTLTMDQI 
EEYLSQLPYL 
HOWESPEEWK 
161 
MPFAIPIALA 
FTRWAEEYGP 
AISDYNDFHK 
WFEWELFGIA 
LRWIPNTRME 
SMLLWETWIE 
NAWFHETLRK 
PERFLDPKFD 
TABLE 
Sequences disclosed 
ALSWLFLFYI 
IYSIRTGAST 
MIKRYILSNW 
LKQAFGKDIE 
TKIORLYFRR 
TADTTMVTTE 
KWSFFSNKSA 
MVVLNTTOVA 
LGPSAOKRHR 
KPIYWEELGT 
KAWMTALINE 
WAMYEWAKDS 
HSPAALWPLR YAHEDTOLGG 
PMDLYKTMAF GAGKRWCAGS 
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14- Continued 
herein. 
OAKLPPVPVV 
KEAMWTRYLS 
SNRDTLRANW 
TLSRDEIFKW 
QKKRIASGEE 
KRODRLYOEI 
YYIPAGTEIA 
LOAMLIACPT 
KLRDGEEENW DTWGLTTHKR YPMHAILKPR. S 
0207 Having described the invention in detail and by 
reference to specific embodiments thereof, it will be appar 
ent that modifications and variations are possible without 
departing from the scope of the invention defined in the 
appended claims. More specifically, although some aspects 
Aug. 3, 2017 
PGLPWIGNLL 
ISTRKLSNAL 
CSRLHSQWKN 
LWLDIMEGAI 
INCYIDFLLK 
OKWCGSEMVT 
INIYGCNMDK 
IGRLVOEFEW 
of the present invention are identified herein as particularly 
advantageous, it is contemplated that the present invention 
is not necessarily limited to these particular aspects of the 
invention. 
SEQUENCE LISTING 
The patent application contains a lengthy “Sequence Listing section. A copy of the “Sequence Listing is available in 
electronic form from the USPTO web site (http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20170218418A1). 
An electronic copy of the “Sequence Listing will also be available from the USPTO upon request and payment of the 
fee set forth in 37 CFR 1.19(b)(3). 
What is claimed is: 
1. A recombinant host capable of synthesizing a Steviol 
glycoside, comprising a gene encoding a transporter poly 
peptide and/or a gene encoding a transcription factor poly 
peptide that regulates expression of at least one transporter 
gene. 
wherein expression of the gene encoding the transporter 
polypeptide and/or the gene encoding the transcription 
factor polypeptide that regulates expression of at least 
one transporter gene is modified and the recombinant 
host transports at least a portion of the synthesized 
Steviol glycoside from the host into a culture medium. 
2. The recombinant host of claim 1, wherein the gene 
encoding the transporter polypeptide is an endogenous gene. 
3. The recombinant host of any one of claim 1 or 2, 
wherein the transporter polypeptide comprises an ATP 
binding cassette (ABC) transporter, a major facilitator Super 
family (MFS) transporter, an amino acid/auxin permease 
(AAAP) family transporter, an ATPase transporter, a sulfate 
permease (SulP) family transporter, a lysosomal cystine 
transporter (LCT) family transporter, a Ca2+:cation anti 
porter (CaCA) family transporter, an amino acid-polyamine 
organocation (APC) Superfamily transporter, a multidrug/ 
oligosaccharidyl-lipid/polysaccharide (MOP) transporter, a 
ZRT/IRT-like protein (ZIP) metal transporter family trans 
porter, a mitochondrial protein translocase (MPT) family 
transporter, a Voltage-gated ion channel (VIC) family trans 
porter, a monovalent cation: proton antiporter-2 (CPA2) fam 
ily transporter, a ThrE family of putative transmembrane 
amino acid efflux transporter, an oligopeptide transporter 
(OPT) family transporter, a K transporter (Trk) family 
transporter, a bile acid:Na symporter (BASS) family trans 
porter, a drug/metabolite transporter (DMT) superfamily 
transporter, a mitochondrial carrier (MC) family transporter, 
an auxin efflux carrier (AEC) family transporter, an ammo 
nia channel transporter (Amt) family transporter, a metalion (Mn"-iron) transporter (Nramp) family transporter, a tran 
sient receptor potential Ca" channel (TRP-CC) family 
transporter, an arsenical resistance-3 (ACR3) family trans 
porter, a nucleobase:cation symporter-1 (NCS1) family 
transporter, an inorganic phosphate transporter (PiT) family 
transporter, an arsenite-antimonite (Ars AB) efflux family 
transporter, an IISP family of transporter, a glycerol uptake 
(GUP) family transporter, a metal ion transport (MIT) 
family transporter, a copper transport (Ctr) family trans 
porter, or a cation diffusion facilitator (CDF) family trans 
porter. 
4. The recombinant host of any one of claims 1-3, wherein 
modified expression comprises: (a) overexpressing the gene encoding the transporter 
polypeptide and/or the gene encoding the transcription 
factor polypeptide; or (b) deleting the gene encoding the transporter polypeptide 
and/or the gene encoding the transcription factor poly 
peptide. 
5. The recombinant host of any one of claims 1-4, wherein 
the gene encoding the transporter polypeptide and/or the 
gene encoding the transcription factor polypeptide has an 
activity that is increased. 
6. The recombinant host of any one of claims 1-5, wherein 
one or more of the genes encoding the transporter polypep 
tide and/or one or more of the gene encoding the transcrip 
tion factor polypeptide is overexpressed. 
7. The recombinant host of claim 6, wherein the trans 
porter polypeptide and/or transcription polypeptide com 
prise YAL067C set forth in SEQID NO:14, YBL089W set 
forth in SEQ ID NO:15, YBL099W set forth in SEQ ID 
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(b) the CDPS polypeptide comprises a polypeptide having 
at least 70% identity to an amino acid sequence set 
forth in SEQ ID NO:150; (c) the KO polypeptide comprises a polypeptide having at 
least 70% identity to an amino acid sequence set forth 
in SEQ ID NO:152: (d) the KS polypeptide comprises a polypeptide having at 
least 40% identity to an amino acid sequence set forth 
in SEQ ID NO:151: (e) the KAH polypeptide comprises a polypeptide having 
at least 60% identity to an amino acid sequence set 
forth in SEQ ID NO:154; (f) the CPR polypeptide comprises a polypeptide having 
at least 70% identity to an amino acid sequence set 
forth in SEQID NO: 153 and/or a polypeptide having at 
least 65% identity to an amino acid sequence set forth 
in SEQ ID NO:155; (g) the UGT85C2 polypeptide comprises a polypeptide 
having at least 55% identity to an amino acid sequence 
set forth in SEQ ID NO:156; (h) the UGT76G1 polypeptide comprises a polypeptide 
having at least 50% identity to an amino acid sequence 
set forth in SEQ ID NO:158: (i) the UGT74G1 polypeptide comprises a polypeptide 
having at least 55% identity to an amino acid sequence 
set forth in SEQ ID NO:157: 
(j) the a UGT91D2 functional homolog comprises a 
UGT91D2e-b polypeptide having at least 90% identity 
to the amino acid sequence set forth in SEQ ID 
NO:159; and 
(k) the EUGT11 polypeptide comprises a polypeptide 
having at least 65% identity to an amino acid sequence 
set forth in SEQ ID NO:148. 
13. The recombinant host of any one of claims 1-12, 
wherein the recombinant host comprises a microorganism 
that is a plant cell, a mammalian cell, an insect cell, a fungal 
cell, or a bacterial cell. 
14. The recombinant host of claim 13, wherein the bac 
terial cell comprises Escherichia bacteria cells, Lactobacil 
lus bacteria cells, Lactococcus bacteria cells, Cornebacte 
rium bacteria cells, Acetobacter bacteria cells, 
Acinetobacter bacteria cells, or Pseudomonas bacterial cells. 
15. The recombinant host of claim 13, wherein the fungal 
cell is a yeast cell. 
16. The recombinant host of claim 15, wherein the yeast 
cell is a cell from Saccharomyces cerevisiae, Schizosaccha 
romyces pombe, Yarrowia lipolytica, Candida glabrata, 
Ashbya gossypii, Cyberlindnera jadinii, Pichia pastoris, 
Kluyveromyces lactis, Hansenula polymorpha, Candida boi 
dinii, Arxula adeninivorans, Xanthophyllomyces den 
drorhous, or Candida albicans species. 
17. The recombinant host of claim 16, wherein the yeast 
cell is a Saccharomycete. 
18. The recombinant host of claim 17, wherein the yeast 
cell is a cell from the Saccharomyces cerevisiae species. 
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19. A method of producing a Steviol glycoside, compris 
1ng: 
(a) growing the recombinant host of any one of claims 
1-18 in a culture medium, under conditions in which 
the genes discussed in any one of claims 1 to 18 are 
expressed, 
wherein the steviol glycoside is synthesized by the 
host; and (b) optionally isolating the Steviol glycoside. 
20. The method of claim 19, wherein the Steviol glycoside 
is RebA, RebB, RebD, and/or RebM, and wherein: (a) RebA is capable of being synthesized in the recom 
binant host of any one of claims 1-18 expressing 
UGT85C2, UGT76G1, UGT74G1, and UGT91D2: (b) RebB is capable of being synthesized in the recom 
binant host of any one of claims 1-18 expressing 
UGT85C2, UGT76G1, and UGT91D2: (c) RebD is capable of being synthesized in the recom 
binant host of any one of claims 1-18 expressing 
UGT85C2, UGT76G1, UGT74G1, and UGT91D2 and/ 
or EUGT11; and (d) RebM is capable of being synthesized in the recom 
binant host of any one of claims 1-18 expressing 
UGT85C2, UGT76G1, UGT74G1, and UGT91D2 and/ 
Or EUGT11 
21. The method of claim 19 or 20, wherein a gene 
encoding YBR043C set forth in SEQID NO:88, YDL100C 
set forth in SEQ ID NO:95, YDL054C set forth in SEQ ID 
NO:94, YDL128W set forth in SEQID NO:22, YDL198C 
set forth in SEQID NO:146, YDR061W set forth in SEQID 
NO:26, YDR536W set forth in SEQ ID NO:30, YEL027W 
set forth in SEQ ID NO:102, YFLO54C set forth in SEQ ID 
NO:147, YGL167C set forth in SEQID NO:112, YGR181W 
set forth in SEQ ID NO:38, YHL016C set forth in SEQ ID 
NO:42, YIL166C set forth in SEQID NO:121, YJL093C set 
forth in SEQ ID NO:44, YJR106W set forth in SEQ ID 
NO:48, YKL120W set forth in SEQID NO: 126, YKL146W 
set forth in SEQID NO.127, YKR039W set forth in SEQID 
NO:129, YMR034C set forth in SEQID NO:56, YMR166C 
set forth in SEQID NO:132, YOL122C set forth in SEQ ID 
NO:68, YOR079C set forth in SEQ ID NO:69, YPL27OW 
set forth in SEQ ID NO:79, and/or YPR011C set forth in 
SEQ ID NO:82 is overexpressed. 
22. The method of any one of claims 19-21, wherein the 
Steviol glycoside is produced at a concentration of between 
about 500 mg/L to about 10,000 mg/L. 
23. A method of increasing production or transport of a 
Steviol glycoside into a culture medium, comprising: 
(a) growing the recombinant host of any one of claims 
1-18 in a culture medium, under conditions in which 
the genes discussed in any one of claims 1 to 18 are 
expressed, 
wherein the steviol glycoside is synthesized by the 
host; and (b) optionally isolating the Steviol glycoside. 
24. The method of claim 23, wherein the Steviol glycoside 
is RebA, RebB, RebD, and/or RebM. 
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